The Clinical Determinants of Plasma β-amyloid and Its Association with Structural and Functional Vascular Changes by Tuharska, Zofia
                                                                          
University of Dundee
MASTER OF SCIENCE







Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 22. Jul. 2021
The Clinical Determinants of Plasma 
β-amyloid and Its Association with 
Structural and Functional Vascular 
Changes 
Zofia Tuharska 
University of Dundee 




















Background: β-amyloid plaque deposition is a pathological hallmark of Alzheimer’s 
disease and cerebral amyloid angiopathy. However, β-amyloid has also been shown 
to possess direct vasoactive properties and increased plasma β-amyloid has been 
associated with endothelial dysfunction in mice. 
Aims: To investigate the metabolic and pharmacological determinants of plasma β-
amyloid levels and to investigate the association of plasma β-amyloid with structural 
and functional markers of vascular integrity as well as cardiovascular outcomes. 
Methods: Plasma  β-amyloid 40 and β-amyloid 42 levels were measured in 407 
subjects with type 2 diabetes (T2DM) and 245 subjects without T2DM from the 
Surrogate markers for Micro and Macro vascular hard endpoints for Innovative 
diabetes Tools (SUMMIT) consortium database. The SUMMIT database was used to 
analyse factors associated with altered plasma β-amyloid levels and to determine 
the relationship between plasma β-amyloid and biomarkers of cardiovascular health 
and disease. Biomarkers analysed included, reactive hyperaemia index (RHI) with 
EndoPAT, reactive hyperaemia in response to occlusion, arterial stiffness, skin 
microcirculation response to acetylcholine (ACh) and sodium nitroprusside (SNP) and 
carotid intima-media thickness (IMT). 
Results: In the SUMMIT baseline cohort as well as in T2DM and non-T2DM sub-
groups, renal function as estimated by estimated glomerular filtration rate (eGFR) 
was the most significant independent predictor of plasma β-amyloid 40 and 42 
levels. In the T2DM subgroup, insulin use was also found to be independently 
associated with increased β-amyloid 40 and 42 levels. Use of diuretics was 
independently associated with increased β-amyloid 40 and 42 levels in the SUMMIT 
baseline cohort and increased β-amyloid 40 levels in the T2DM cohort. After 
adjusting for conventional cardiovascular risk factors of age, gender, diabetes status, 
systolic blood pressure (SBP), high-density lipoprotein (HDL) cholesterol and total 
cholesterol as well as independent predictors of plasma β-amyloid, β-amyloid 40 was 
independently associated with increased arterial stiffness as measured by pulse 
wave velocity, and reduced vascular responsiveness to ACh and SNP in the SUMMIT 
baseline and SUMMIT T2DM cohorts. β-amyloid was not found to be a significant 
predictor of cardiovascular outcomes over 4-6 years of follow up.  
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Conclusions: The research in this thesis shows that plasma β-amyloid levels are 
affected by a range of metabolic and pharmacological factors. Future studies should 
therefore take into account the importance of adjusting for factors such as eGFR, 
diuretic use or insulin use. The results also show that higher levels of β-amyloid 40, 
and to a lesser extent 42, are associated with increased arterial stiffness as well as 
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 The Burden of Cardiovascular Disease  
 
In recent years, non-communicable diseases such as cardiovascular disease (CVD), 
stroke and diabetes have become the number one killers in the world. In the UK, 
CVD is responsible for approximately 26% of all deaths and is thus a major public 
health concern of the nation (1). The global obesity and diabetes epidemic has risen 
hand in hand with the rise in proportion of deaths caused by CVD. It is now 
estimated that in the UK, 1 in every 16 people has diabetes, which equates to more 
than double the rates seen 20 years ago (2).  Yet, more concerning statistics suggest 
that almost a third of all adults in England are now classified as being obese, with a 
body mass index (BMI) > 30 (2). Due to these prevailing trends, the burden of CVD is 
expected to rise even further and as such, many nations have made it a priority to 
tackle this epidemic by means of primary prevention (3). From a therapeutic 
perspective, several classes of pharmacological agents exist, ranging from lipid 
lowering therapy, glucose lowering agents or anti-hypertensive drugs. However, 
given that a significant proportion of the adult population is now likely to have 
diabetes or obesity, it has become a challenge to identify those people at highest risk 
of cardiovascular complications. Therefore, there is an increasing need to explore 
new methods to improve stratification of the population at risk. 
 
 Biomarkers of Cardiovascular Disease  
 
A biomarker is defined as a naturally occurring molecule, gene or characteristic by 
which a particular pathological or physiological process can be identified (4). Major 
studies carried out in the 1960s and onwards have provided insight into biomarkers 
associated with an increased risk of CVD. As a result, the term “risk factor” was 
coined to describe factors such as hypertension, diabetes, smoking or 
hypercholesterolaemia (5). These have in turn been combined to create 
comprehensive risk score calculators, predicting a patient’s risk of developing 
cardiovascular disease. Over 50 years later, knowledge gained from these studies 
still hold true and are in widespread use clinically.  
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The hallmark Framingham Heart Study was the first large-scale prospective cohort 
study that set out to investigate the epidemiology and aetiology of atherosclerotic 
and hypertensive CVD (5). The original study cohort consisted of 5,209 adults from 
Framingham, USA, aged 30-62 years. Additionally, an off-spring cohort and third 
generation cohort were then studied (6). As such, the Framingham heart study was 
not only one of the first studies to provide information on the aetiology of CVD, but 
also provided valuable information about the heritability of these conditions and 
common comorbidities such as obesity or diabetes. Based on this information, the 
first method for calculating cardiovascular risk scores, the Framingham Risk Score, 
was developed (5). Using factors such as age, gender, total cholesterol, high density 
lipoprotein (HDL) cholesterol, smoking, diabetes and blood pressure, it calculates an 
individual’s 10-year risk of developing CVD. Other risk scores that have since been 
developed but operate on a similar principle include the locally used ASSIGN risk 
score, which also takes into account social deprivation (7), or the SCORE (Systemic 
COronary Risk Evaluation) based on a pooled dataset of 12 European Prospective 
Cohort Studies (8). Although subtle differences between the various risk scores exist, 
they predict risk based on the same set of biomarkers.  
Limitations of Conventional Biomarkers and Cardiovascular Risk Scores 
Plasma lipid levels are cited as one of the major risk factors for the development of 
CVD and are thus included in all conventional CVD risk scores. However, a number of 
limitations of conventional biomarkers exist. Despite extensive research, studies 
have shown that as many as 50% of individuals who develop coronary heart disease 
have only one risk factor, and in some age groups, up to 35% of individuals have no 
conventional CVD risk factors (9). A recent study by Sachdeva et al. found that a 
substantial proportion of patients presenting with acute myocardial infarction across 
hospitals in the United States had lipid levels within the recommended range at time 
of presentation. Of the 48,093 patients without prior history of coronary artery 
disease, other atherosclerotic disease or diabetes, 41.5% had low density lipoprotein 
(LDL) cholesterol levels <2.6mmol/L (10). In the UK, estimates suggest that over half 
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of the adult population have elevated cholesterol levels (11). Due to extensive 
primary prevention campaigns, the majority of patients identified as being at risk of 
CVD are likely to be taking statins. Indeed, a cross-sectional study of the prevalence 
of primary prevention statin prescriptions showed that between 2009-2011, 
estimated prevalence of statin use was as high as 30% in subjects aged 50 years and 
over (12).  It is possible, that widespread use of lipid lowering agents could account 
for relatively low-normal cholesterol levels among patients with acute coronary 
syndromes. Understanding the effects of risk factor modifying therapies on the 
predictive value of established risk scores is therefore extremely important. 
However, a recent review of CVD risk scores found that none of them accounted for 
the effects of risk modifying treatment such as statin use. (13) Therefore, while 
biomarkers such as LDL and HDL may be of use in predicting CVD risk in a statin-
naïve population, their predictive value in the general population with widespread 
statin use is unclear.  
 
As is the case with lipid lowering agents such as statins or fibrates, the use of 
antihypertensive drugs is widespread in the UK. It is well established that lower 
blood pressure is associated with a lower cardiovascular risk (14). However, a 
common but underestimated limitation of blood pressure as a biomarker is the 
inaccuracy associated with one-off clinic measurements. A study looking at blood 
pressure measurements in the primary care setting found that based on poor 
technique, 24-32% of patients were being misdiagnosed as having systolic 
hypertension and 15-21% were being misdiagnosed as having diastolic hypertension 
(15). Consequently, the research into new, easily measurable biomarkers has 
continued and yielded results with varying levels of success.  
 Novel Circulating Biomarkers 
 
Over the last few years, many potential novel biomarkers of CVD risk have been 
investigated. Broadly, these can be grouped into numerous categories including 
inflammatory biomarkers, metabolic biomarkers as well as biomarkers of vascular 
remodelling. While it is beyond the scope of this thesis to discuss all of these 
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promising novel circulating biomarkers, the following table aims to summarise some 
of those most commonly discussed in the literature.  
 
Table 1-1: A summary of potential novel circulating biomarkers of CVD risk, table 
adapted from (16), for abbreviations see list of abbreviations. 
Inflammatory  Metabolic 
CRP (17) 
TNF-alpha (18,19) 








Biomarkers of vascular remodelling  Biomarkers of endothelial dysfunction 










 β-amyloid as a Potential Novel Circulating Biomarker 
 
Another potential, but to date relatively unexplored biomarker of CVD risk is β-
amyloid, a peptide thought to be the hallmark of Alzheimer’s disease (AD). While an 
association between AD, β-amyloid and CVD dates far back, only more recently has 
this association been looked at in further detail. A number of in vitro studies have 
suggested that β-amyloid may possess direct vasoactive properties (31,32). 
However, as a general rule two main limitations of previous studies exist. Firstly, the 
doses of β-amyloid used in studies has often exceeded concentrations seen 
physiologically in organisms. Secondly, β-amyloid peptides are either used freshly or 
allowed to form oligomers and subsequently applied acutely. Neither of these 
scenarios replicate adequately what occurs in vivo, whereby vascular exposure to 
plasma β-amyloid is a of a chronic nature and at much lower concentrations.  
Perhaps most important for this study are the currently unpublished findings by 
Meakin et al. In this animal study, the effect of β-amyloid on endothelial function 
was investigated. Mice with chronic exogenous β-amyloid 42 infusions were found to 
have significantly diminished responses to the vasodilator acetylcholine (ACh) as 
assessed by means of laser Doppler imaging with iontophoresis of vasoactive 
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chemicals in the skin microcirculation. Additionally, by lowering the levels of 
circulating β-amyloid using pharmacological inhibition of an enzyme involved in the 
rate-limiting step of β-amyloid production, the endothelial response to ACh 
improved significantly (33). Given these findings, the next step was to determine 
whether findings in animal models translate into the human population. 
Conveniently, the pre-existing SUMMIT database contained data on plasma β-
amyloid levels as well as laser Doppler imaging and iontophoresis assessments and 
other surrogate structural and functional biomarkers of vascular changes. The 
purpose of this thesis was therefore to build on previous findings of the research 
group and, using statistical analysis of data from pre-existing databases, determine 
whether plasma β-amyloid could serve as a biomarker of CVD risk. More specifically, 
the aim was to determine whether in humans, similar associations between plasma 
beta-amyloid and skin microcirculation function exist, whether any associations exist 
between plasma β-amyloid and other surrogate markers of vascular structure and 
function and whether plasma β-amyloid levels are associated with adverse 
cardiovascular outcomes. However, due to the very limited knowledge of the 
physiological and pathophysiological properties of plasma β-amyloid out with the 




2  An exploration of the biochemical, metabolic and 
pharmacological factors affecting plasma β-amyloid levels 




 β Amyloid Production 
 
Aβ is a ~4kDa peptide extensively researched primarily in the context of Alzheimer’s 
disease (AD) (34) (35). In this pathological state, intracerebral accumulation of 
plaques consisting of β-amyloid represent a pathological hallmark. While the role of 
β-amyloid in the development of AD is well established, its role in both other disease 
processes and physiological processes is currently unknown. Present in high 
concentrations in the brain, β-amyloid is also found in a number of other human 
tissues including skeletal muscle, liver and kidney (36).  In recent years, several 
studies have suggested that plasma β-amyloid is associated with CVD and may even 
directly contribute to the pathophysiological process (37–39). However, before the 
potential predictive value of plasma β-amyloid in establishing CVD risk is 
determined, more information is required about factors affecting plasma β-amyloid 
concentrations. The following review will therefore aim to summarise steps in β-
amyloid production, as well as our current knowledge of clinical determinants of 
plasma β-amyloid.  
 
β-amyloid is formed by the sequential processing of its precursor molecule, amyloid 
precursor protein (APP) (40). APP can be processed down either a non-
amyloidogenic pathway, which predominates in health, but also down an 
amyloidogenic pathway yielding Aβ peptides. The latter is thought to predominate in 
pathological conditions such as Alzheimer’s disease. The first and rate-limiting step 
in the amyloidogenic pathway is cleavage of APP by β-secretase (BACE1) (Figure 2.1 
image from (41). This results in the formation of a membrane bound fragment C99 
and a secreted fragment. C99 is further cleaved by gamma-secretase, however, 
gamma-secretase has a non-specific cleavage site resulting in the formation of a 
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Figure 2-1: Fate of amyloid precursor protein when processed down 
different pathways. BACE1 mediates beta-cleavage (41). 
range of different peptides with varying amino acid lengths. Among the different Aβ 
peptides, Aβ40 is the most abundant form, while Aβ42 is the main pathological form 
implicated in AD (42).   
While the processes leading to β-amyloid production have been well mapped out, β-
amyloid degradation or excretion is less understood. A number of different 
proteases have been implicated in the degradation of β-amyloid peptides. These 
include metalloproteases such as neprilysin, endothelin converting enzymes, 
angiotensin converting enzyme, insulin degrading enzyme as well as matrix 
metalloproteinases 2 and 9 (43) (44–47). Interestingly, all of these proteases have 
been extensively linked to a number metabolic and CVD processes.  
Known Clinical Determinants of β-amyloid Peptides 
Although β-amyloid has been investigated primarily in the brain, the discovery of 
methods enabling the measurement of circulating peripheral β-amyloid have 
unveiled associations with several different clinical determinants.  
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A number of studies emerged in the 1990s that, for the first time, depicted an 
epidemiological association between AD and type 2 diabetes mellitus (T2DM). The 
Hisiyama study in 1995 reported a relative risk (RR) of 2.18 for AD in patients with 
type 2 diabetes (48). A study published some years later from the same group made 
the interesting observation that the RR of AD was greater than that of vascular 
dementia in patients with diabetes (RR 2.05 vs RR 1.82) (49). These observations 
prompted further research into the link between the pathogenesis of AD and that of 
diabetes. Since then, several studies have shown that not only do pathological 
processes in patients with diabetes predispose individuals to AD, there is also 
evidence showing that this is a bi-directional relationship. Indeed, several studies 
discussed below have shown that Aβ affects processes relevant to diabetes such as 
glucose handling and energy homeostasis. Several independent research groups 
have found that non-diabetic patients with AD have evidence of impaired glucose 
tolerance (50). This would suggest that there is perhaps a link between β-amyloid 
and some earlier stages of type 2 diabetes. Further reinforcing these findings, a 
study examining 101 pre-school children and 309 adolescent children found that 
obese adolescent children had significantly higher levels of circulating Aβ42 when 
compared to normal-weight peers but no significant difference in Aβ42 was 
observed between obese and normal-weight pre-school children. They found a 
significant positive correlation between plasma Aβ42 levels and BMI as well as 
estimated insulin resistance (HOMA-IR) (51). Another study reported that plasma β-
amyloid levels were found to increase after glucose loading in patients with AD (52). 
This is assumed to occur due to a rise in insulin secretion, as other studies have 
shown that plasma β-amyloid levels increase following exogenous insulin 
administration and that plasma β-amyloid levels positively correlate with plasma 
insulin levels (53).  Additionally, β-amyloid is found in high concentrations in the 
pancreas. While the reason behind this observation remains unclear, post mortem 
analysis of pancreas tissue from 21 patients with type 2 diabetes revealed 
accumulation of Aβ aggregates within the Islets of Langerhans (54). 
A number of other clinical determinants of plasma β-amyloid have also been 
reported.  Several studies have consistently reported an association between 
increasing age and higher levels of plasma β-amyloid levels (55). Findings of 
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significant associations between plasma β-amyloid and creatinine levels have also 
been consistent in the literature (56).  A study of 997 older adults showed that 
African-American race was associated with lower levels of both plasma β-amyloid 40 
and 42. Additionally this study also reported a significant association between 
female gender and lower plasma β-amyloid 42 levels (57). However, the majority of 
these studies were done in the context of AD research and as such, primarily 
enrolled elderly individuals.   
 
 
 Effect of Pharmacological Agents on Plasma β-amyloid 
 
In an attempt to investigate the possibility of using plasma β-amyloid concentrations 
as a biomarker of CVD or AD, a number of studies had set out to determine the 
effects of medications on plasma levels. One prospective cohort based study 
followed up 487 subjects with plasma Aβ42 levels measured at baseline and 2.5 
years’ follow up. The study found a significant association between use of insulin and 
increased Aβ42 levels at follow up. The herbal supplement gingko biloba as well as 
fibrates were associated with reduced plasma Aβ42 levels at follow up. There was no 
association with statins, or non-steroidal anti-inflammatory medications (NSAIDs) 
and plasma β-amyloid 40 levels were not investigated in this study (58). Another 
cross sectional study looked at 371 patients with different forms of cognitive 
impairment. They found no association with plasma β-amyloid 42 levels and 
cholinesterase inhibitors, vitamin E, statins, NSAIDs or oestrogens. As with the 
previous study, plasma β-amyloid 40 levels were not measured (55). In rats, a study 
looking at the effect of various antidepressant medications on a β-amyloid induced 
depression-like state found that administration of fluoxetine was associated with 
reduced soluble plasma β-amyloid levels. No association was found with other 
selective serotonin reuptake inhibitors used in this study. Additionally, this study did 







A large number of circulating molecules have in the past been investigated as 
potential biomarkers of CVD risk. However, very few findings have translated into 
routine clinical practice. While circulating biomarkers may be shown to predict CVD 
or outcomes, a lack of knowledge about factors affecting their concentrations are 
often cited as major limiting factors. Therefore before investigating β-amyloid as a 
potential new CVD risk biomarker, the following analysis will aim to determine what 





The hypothesis is that there is a significant association between circulating β-amyloid 






























The Surrogate markers for Micro and Macro vascular hard endpoints for Innovative 
diabetes Tools (SUMMIT) database was used for the purpose of this study. The 
original SUMMIT cohort consisted of subjects recruited from existing population 
cohorts and hospital registers at the university hospitals in Malmö (Sweden), Pisa 
(Italy), Dundee and Exeter (UK) between December 2010 and April 2013 (60,61). For 
the purpose of this study, only subjects recruited in Exeter and Dundee were used 
due to availability of plasma β-amyloid and skin microvascular measurements.  
Therefore, in this study the term SUMMIT cohort refers to a total of 652 subjects 
recruited at centres in Dundee and Exeter between December 2010 and April 2013, 
with health outcome follow up until April 2017. The baseline cohort was divided into 
4 subgroups depending on type 2 diabetes and CVD status: 
1. Patients with diabetes and clinically manifest CVD (n=189),
2. Patients with diabetes but without clinically manifest CVD (n=218)
3. Patients without diabetes but with clinically manifest CVD (n=125)
4. Patients without diabetes and without clinically manifest CVD (n=120).
Diabetes was defined as current or previous episodes of hyperglycaemia (fasting 
plasma glucose >7.0 mmol/l or random plasma glucose >11.1 mmol/l) or by current 
treatment with metformin, sulphonylureas or other glucose lowering agents. 
Clinically manifest CVD was defined as a past medical history of acute MI, unstable 
angina requiring hospitalisation, coronary revascularisation procedures, stroke, 
transient ischaemic attack confirmed by specialists, peripheral vascular disease 
defined as ankle-brachial pressure index (ABPI) <0.9 and intermittent claudication or 
prior angioplasty/ above ankle amputation. Subjects with diabetes were matched 
across centres for gender, age and duration of diabetes. Subjects without diabetes 
were matched for gender and age across centres. Exclusion criteria at recruitment 
were renal replacement therapy, malignancy requiring active treatment, end-stage 
renal disease, chronic inflammatory disease on therapy, previous bilateral carotid 
artery invasive interventions or age <40 years (61). Plasma β-amyloid was measured 
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as a one-off measurement using the Quanterix β-amyloid assay on the Simoa HD-1 
analyser (62). This allowed for a more sensitive measure at the lower ranges of β-
amyloid concentrations compared to other available platforms. The study was 
approved by the local ethical review boards and performed in accordance with the 
principles of the Declaration of Helsinki. All study subjects provided written informed 
consent. 
Statistical Analysis of Clinical Patient Characteristics and Plasma β-amyloid 
All statistical analysis was performed using the IBM SPSS software version 25. Due to 
population size, data distribution was assessed for normality using the Shapiro-Wilk 
test with Kolmogorov-Smirnov used as a reference. For the analysis of continuous 
variables univariate correlations were used. Where both variables had a normal 
distribution, Pearson’s correlation was used. Where variables were found to not 
have a normal distribution, Spearman’s rho was used. To adjust for multiple 
comparisons, the Bonferroni method was used to adjust the level of significance. By 
dividing the standard level of significance, p=0.05, by the number of comparisons 
made a new level of significance was established. In order to analyse the association 
between plasma β-amyloid and binary determinants such as gender, CVD status, 
T2DM status or medications use, the Mann-Whitney or Independent T-tests were 
used, depending on the distribution of variables. Based on significant univariate 
correlations and associations from the above analyses, linear regression was used to 
determine independent predictors of plasma β-amyloid 40 and 42 levels in the 
SUMMIT baseline cohort as well as in subgroups divided based by diabetes status.  
Results 
SUMMIT Population Descriptive Statistics 
As mentioned before, the SUMMIT cohort consists of 4 groups based on diabetes 
and CVD status. The following table summarises the baseline characteristics of the 
SUMMIT cohort. Where the variable presented is a count, the number in brackets 
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represents the equivalent %, where the number presented is a continuous variable, 
the number in brackets represents the standard deviation of that variable. Where 
significant differences exist between groups, the significance is illustrated using an 
asterisk (*= p<0.05, **= p<0.01, *** = p<0.001). SBP= systolic blood pressure, T2D = 
type 2 diabetes, DBP = diastolic blood pressure, eGFR = estimated glomerular 
filtration rate, ACR = albumin:creatinine ratio). 
Table 2-1: Summary of baseline patient characteristics in the SUMMIT cohort. 
SUMMIT Cohort 








N 189 218 120 125 
Males n (%)  *** 142 (75%) 120 (55%) 53 (44%) 94 (75%) 
Age (SD) *** 67.7 (8.0) 63.9 (8.7) 63.1 (8.0) 68.5 (7.5) 
T2D Duration (years) *** 12.0 (8.3) 8.6 (6.1) NA NA 
BMI (kg/m2) *** 31.3 (5.1) 32.6 (5.9) 26.8 (4.3) 28.1 (4.1) 
Medication         
Statin use *** 168 (89%) 162 (74%) 20 (17%) 108 (86%) 
Antihypertensive use 
*** 
169 (89%) 138 (63%) 18 (15%) 93 (74%) 
Blood Pressure         
SBP *** 132.5 (18.1) 133.2 
(16.3) 
130.2 (16.4) 131.5 (18.3) 
DBP  73.1 (8.2) 77.3 (8.8) 77.1 (9.0) 74.8 (8.9) 
Metabolic parameters         
HbA1c mmol/mol *** 61.9 (15.6) 59.0 (14.8) 40.1 (4.1) 39.0 (3.3) 
Total Cholesterol 
mmol/l *** 
3.8 (0.9) 4.1 (0.9) 5.4 (1.0) 4.2 (0.9) 
LDL Cholesterol mmol/l 
*** 
1.8 (0.7) 2.0 (0.8) 3.1 (0.9) 2.2 (0.8) 
HDL Cholesterol mmol/l 
*** 
1.2 (0.3) 1.3 (0.4) 1.6 (0.4) 1.4 (0.4) 
Triglycerides mmol/l *** 1.8 (1.1) 1.8 (1.0) 1.4 (0.8) 1.3 (0.7) 
Renal Function         
Serum Creatinine umol/l 
*** 
92.6 (33.2) 78.0 (20.3) 74.3 (13.7) 84.0 (19.4) 
ACR mg/mmol *** 6.9 (34.3) 2.7 (5.5) 0.9 (1.1) 1.9 (4.3) 
eGFR mL/min/1.73 m² *** 
 







Figure 2-2: Scatterplot of β-amyloid 40 and 42 in n=643 
subjects, r=0.494, p=1.1E-40. 
 Association between Plasma β-amyloid 40 and 42 
 
Before investigating the associations between plasma β-amyloid and clinical 
variables, we examined the association between plasma β-amyloid 40 and 42. A 
















 Association of Plasma β-amyloid Levels with Continuous Determinants – 
SUMMIT Cohort 
 
In order to begin exploring the relationship between plasma β-amyloid and baseline 
continuous variables, univariate correlations were first used looking at the whole 
cohort, without subdividing subjects into groups.  
 
Table 2-2: Summary of correlations of plasma β-amyloid 40 and 42 and baseline 
subject characteristics in the SUMMIT cohort. Values shown in bold are significant 
at Bonferroni adjusted p-value 0.003. 




Age (years) Correlation Coefficient 0.178 0.14 
  Sig. 7.00E-06 4.51E-04 
  N 628 628 
Body Mass Index (kg/m2) Correlation Coefficient 0.109 0.046 
  Sig. 0.006 0.253 
  N 628 628 
Height (m) Correlation Coefficient -0.146 -0.104 
  Sig. 1.97E-04 0.008 
  N 642 642 
Weight (kg) Correlation Coefficient 0.024 -0.005 
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  Sig. 0.544 0.902 
  N 642 642 
HbA1c (mmol/mol) Correlation Coefficient 0.099 0.103 
  Sig. 0.013 0.009 
  N 632 632 
Total Cholesterol 
(mmol/l) 
Correlation Coefficient -0.126 -0.125 
  Sig. 0.002 0.002 
  N 632 632 
LDL Cholesterol (mmol/l) Correlation Coefficient -0.14 -0.179 
  Sig. 0.001 1.20E-05 
  N 589 589 
HDL Cholesterol (mmol/l) Correlation Coefficient -0.102 -0.026 
  Sig. 0.011 0.509 
  N 626 626 
Triglycerides (mmol/l) Correlation Coefficient 0.072 0.05 
  Sig. 0.071 0.213 
  N 621 621 
eGFR (mL/min/1.73 m²) Correlation Coefficient -0.354 -0.367 
  Sig. 1.15E-15 8.95E-17 




















Figure 2-3: Scatter plot of age and β-amyloid 40 in n=628 

















































Figure 2-4: Scatter plot of height and β-amyloid 40 in n=642 
subjects, r=-0.146, p=1.97E-4. 
Figure 2-5: Scatter plot of total cholesterol and β-amyloid 40 
in n=632 subjects, r=-0.126. p=0.002. 
Figure 2-6: Scatter plot of LDL cholesterol and β-amyloid 40 


















































Figure 2-7: Scatter plot of eGFR and β-amyloid 40 in n=483 
subjects, r=-0.354, p=1.15E-15. 
Figure 2-8: Scatter plot of age with β-amyloid 42 in n=628 
subjects, r=0.140, p=4.5E-4. 
Figure 2-9: Scatterplot of total cholesterol with β-amyloid 


































Based on the above analysis of the baseline SUMMIT cohort, a significant positive 
correlation exists between β-amyloid 40 and age, while significant negative 
correlations are present between β-amyloid 40 and height, LDL cholesterol, total 
cholesterol as well as eGFR. Similarly, for β-amyloid 42, a significant positive 
correlation was observed with age, and significant negative correlations with LDL 





Figure 2-10: Scatter plot of LDL cholesterol with β-amyloid 42 in 
n=589 subjects, r=-0.179, p=1.2E-5. 
Figure 2-11: Scatter plot of eGFR with β-amyloid 42 in n=482 
subjects, r=-0.367, p=8.9E-17. 
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Figure 2-13: Comparison of β-amyloid 40 levels in subjects without and 
with CVD, n=334, n=309 respectively. 
 Effect of Binary Determinants on Plasma β-amyloid levels – SUMMIT Cohort 
 
As the first step in exploring the relationship between plasma β-amyloid levels and 
binary determinants, the distribution of variables was assessed. Due to the 
distribution of variables, the Mann-Whitney test was use to compare plasma β-
amyloid levels. The figures below summarise the results of mean comparisons for 
the following set of binary determinants: diabetes status, CVD status, gender, ACE 
inhibitor use, angiotensin II receptor blocker use, Β-blocker use, calcium channel 
blocker use, diuretic use, fibrate use, NSAID use, nitrite use, statin use and steroid 
use. Results for β-amyloid 40 are presented first followed by β-amyloid 42. With a 
total of 26 comparisons made, the new value for significance was set at p<0.002 at 


















Figure 2-12: Comparison of β-amyloid 40 levels in subjects 
without and with diabetes, n=244, n=399 respectively. 
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Figure 2-14: Comparison of β -amyloid 40 levels in females and 















































Figure 2-15: Comparison of β-amyloid 40 levels in subjects without and 
with ACE inhibitor use, n=383, n=256 respectively 
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Figure 2-16: Comparison of β-amyloid 40 levels in subjects without and 
with angiotensin II receptor blocker use, n =515, n=118 respectively. 
Figure 2-18: Comparison of β-amyloid 40 levels in subjects without and 
with β-blocker use, n=448, n=190 respectively 
Figure 2-17: Comparison of β-amyloid 40 levels in subjects without and 

























Figure 2-19: Comparison of β-amyloid 40 levels in subjects without and 
with diuretic use, n=479, n=158 respectively. 
Figure 2-21: Comparison of β-amyloid 40 levels in subjects without and with 









































Figure 2-20: Comparison of β-amyloid 40 levels in subjects without 
























Figure 2-23: Comparison of β-amyloid 40 levels in subjects without and with statin 














Figure 2-24: Comparison of β-amyloid 40 levels in subjects without and with 
steroid use, n=611, n=22 respectively. 
 
Figure 2-22: Comparison of β-amyloid 40 levels in subjects without and with 
NSAID use, n=617, n=17 respectively 
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Figure 2-26: Comparison of β-amyloid 42 levels in subjects without 
and with CVD, n=334, n=309 respectively. 
Figure 2-27: Comparison of β-amyloid 42 levels in female and male subjects, 













































Figure 2-25: comparison of β-amyloid 42 levels in subjects without 
and with T2DM, n=244, n=399 respectively. 
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Figure 2-28: Comparison of β-amyloid 42 levels in subjects without 
and with ACE inhibitor use, n=384, n=255 respectively. 
Figure 2-29: Comparison of β-amyloid 42 levels in subjects without and 
with angiotensin II receptor blocker use, n=516, n=118 respectively. 
Figure 2-30: Comparison of β-amyloid 42 levels in subjects without 

















































Figure 2-31: Comparison of β-amyloid 42 levels in subjects without 
and with calcium channel blocker use, n=480, n=158 respectively. 
Figure 2-32: Comparison of β-amyloid 42 levels in subjects without and 
with diuretic use, n=479, n=158 respectively. 
Figure 2-33: Comparison of β-amyloid 42 levels in subjects without 
















































Figure 2-34: Comparison of β-amyloid 42 levels in subjects without 
and with NSAID use, n=618, n=17 respectively. 
Figure 2-36: Comparison of β-amyloid 42 levels in subjects without and 
with nitrite use, n=540, n=97 respectively. 
Figure 2-35: Comparison of β-amyloid 42 levels in subjects without 
















































Figure 2-37: Comparison of β-amyloid 42 levels in subjects without and with 



















From the above analysis it can be seen that after adjusting for multiple comparisons, 
plasma β-amyloid 40 levels are significantly different when stratifying subjects based 
on angiotensin receptor blocker (ARB) use and diuretic use. β-amyloid 42 levels are 
significantly different when stratifying the population based on diuretic use. Prior to 
adjusting for multiple comparisons, other factors that were associated with 
significantly different levels of β-amyloid 40 at the standard significance level of 
p<0.05 included diabetes status, calcium channel blocker use as well as statin use. At 
the standard significance value of p <0.05, β-amyloid 42 levels were associated with 


















 Regression Analysis of Independent Predictors of β-amyloid - SUMMIT 
Cohort 
 
In order to determine which factors are independently associated with plasma β-
amyloid levels in the SUMMIT baseline cohort, a linear regression model was used. 
Significant variables identified from the univariate analyses above were entered into 
the model and selected using forward selection, the p-value cut off for inclusion in 
the model was set at p=0.05. Forward selection was used to arrive at the final model. 
B refers to the unstandardized regression coefficient which represents the slope of 
the model associated with a 1 unit change in the independent variable. Βeta-refers 
to the standardised regression coefficient and allows for direct comparison of the 
effects of independent variables.  
 
 
Table 2-3: Regression model, with independent variables age, BMI, diabetes status, height, 
HbA1c, total cholesterol, LDL cholesterol, HDL cholesterol, eGFR, ARB use, calcium channel 
blocker use, diuretic use, statin use selected using forward selection. 
β-amyloid 40 
Independent Variables B Beta Sig. 
eGFR (mL/min/1.73 m²) -1.007 -0.228 6.26E-08 
Diuretic use 34.28 0.157 1.67E-04 
 
 
Table 2-4: Regression model, with selection independent variables Age, Diabetes status, 
Height, HbA1c, total cholesterol, LDL cholesterol, eGFR, ARB use, Diuretic use, Statin use 
selected using forward selection. 
β-amyloid 42 
Independent Variables B Beta Sig. 
eGFR (mL/min/1.73 m²) -0.071 -0.289 5.44E-12 
LDL Cholesterol (mmol/l) -0.548 -0.099 0.015 
Diuretic Use 1.033 0.085 0.039 
 
 
As can be seen from these regression models, eGFR and diuretic use were the only 
significant independent predictors of β-amyloid 40 after adjusting for the factors 
specified above. For β-amyloid 42, eGFR, LDL cholesterol and diuretic use were the 





 Subgroup Analysis: SUMMIT T2DM Cohort 
 
Having looked at factors affecting plasma β-amyloid concentrations in the SUMMIT 
baseline cohort, the analysis was repeated in diabetes and non-diabetes subgroups. 
This was done in order to determine whether the same factors are independently 
associated with plasma β-amyloid in subjects with and without diabetes. 
Additionally, the effect of different glucose lowering agents on plasma β-amyloid 
levels could also be investigated.  Although diabetes status was not independently 
associated with plasma β-amyloid levels in the analysis of the SUMMIT baseline 
cohort, the association between β-amyloid and T2DM processes previously reported 
in the literature was deemed to be clinically important. Depending on the 
distribution of variables, either Spearman or Pearson correlation was used in 
univariate analyses. In order to correct for multiple comparisons, the Bonferroni 
correction was used, by dividing p<0.05 by number of comparisons made.   As a 
result, p<0.003 was set as the new threshold for significance. Scatterplots for 
significant correlations are displayed below.   
 
Table 2-5: Correlation of plasma β-amyloid and baseline continuous characteristics in the 
SUMMIT T2DM cohort. 
 Variable Correlation Aβ40 (pg/ml) Aβ42 
(pg/ml) 
Age (years) Correlation Coefficient 0.121 0.149 
  Sig. 0.017 0.003 
  N 385 385 
Body Mass Index (kg/m2) Correlation Coefficient 0.097 0.038 
  Sig. 0.056 0.463 
  N 385 385 
Height (m) Correlation Coefficient -0.127 -0.101 
  Sig. 0.011 0.045 
  N 398 398 
Weight (kg) Correlation Coefficient 0.027 0.006 
  Sig. 0.592 0.906 
  N 398 398 
HbA1c (mmol/mol) Correlation Coefficient 0.043 0.04 
  Sig. 0.394 0.433 
  N 391 391 
Total Cholesterol (mmol/l) Correlation Coefficient -0.129 -0.095 
  Sig. 0.01 0.059 
  N 393 393 
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LDL Cholesterol (mmol/l) Correlation Coefficient -0.17 -0.166 
  Sig. 0.001 0.002 
  N 364 364 
HDL Cholesterol (mmol/l) Correlation Coefficient -0.099 -0.036 
  Sig. 0.05 0.477 
  N 390 390 
Triglycerides (mmol/l) Correlation Coefficient 0.088 0.075 
  Sig. 0.085 0.141 
  N 386 386 
eGFR (mL/min/1.73 m²) Correlation Coefficient -0.301 -0.304 
  Sig. 2.67E-09 1.88E-09 
































Figure 2-38: Scatter plot of LDL cholesterol and plasma β-amyloid 40 in the 
SUMMIT T2DM cohort. n=364, r=-0.17, p=0.001. 
Figure 2-39: Scatter plot of eGFR and β-amyloid 40 – SUMMIT T2DM 



































The above analysis of continuous determinants of plasma β-amyloid revealed that in 
the T2DM cohort, a significant negative correlation is exists between both β-amyloid 











Figure 2-40: Scatter plot of LDL cholesterol and plasma β-amyloid 42 – 
SUMMIT T2DM cohort. n=364, r=-0.166, p=0.002. 
Figure 2-41: Scatter plot of eGFR and β-amyloid 42 – SUMMIT T2DM 
cohort. n=375, r=-0.304, p=1.88E-9. 
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Figure 2-42: SUMMIT T2DM cohort - comparison of β-amyloid 40 levels in subjects 
without and with CVD, n=214, n=185 respectively. 
Figure 2-43: SUMMIT T2DM cohort - comparison of β-amyloid 40 levels in females and 
males, n=127, n=258 respectively. 
 Effect of Binary Determinants on Plasma β-amyloid Levels – SUMMIT T2DM 
cohort 
 
To analyse the association of different pharmacological agents with plasma β-
amyloid in the diabetes cohort, new plasma β-amyloid quartiles were calculated 
using only the values of diabetes subjects. In addition to medications analysed in the 
baseline cohort, glucose lowering therapies were also analysed. These included 
biguanides, dipeptidyl peptidase 4 inhibitors, glitazones, incretins, insulin and 
sulphonylureas. For the comparisons below, a p value of <0.002 was set as the new 































Figure 2-44: SUMMIT T2DM cohort - comparison of β-amyloid 40 levels in subjects 
without and with ACE inhibitor use, n=203, n=194 respectively. 
Figure 2-45: SUMMIT T2DM cohort - comparison of β-amyloid 40 levels in subjects 
without and with angiotensin II receptor blocker use, n=297, n=94 respectively. 
Figure 2-46: SUMMIT T2DM cohort - comparison of β-amyloid 40 levels in subjects 


















































Figure 2-49: SUMMIT T2DM cohort - comparison of β-amyloid 40 levels in 
subjects without and with DPP-4 inhibitor use, n=367, n=26 respectively. 
Figure 2-48: SUMMIT T2DM cohort - comparison of β-amyloid 40 levels 

















































Figure 2-47:SUMMIT T2DM cohort - comparison of β-amyloid 40 




Figure 2-50: SUMMIT T2DM cohort - comparison of β-amyloid 40 levels in subjects 
without and with diuretic use, n=266, n=129 respectively. 
Figure 2-51: SUMMIT T2DM cohort - comparison of β-amyloid 40 levels in 
subjects without and with fibrate use, n=367, n=25 respectively. 
Figure 2-52: SUMMIT T2DM cohort - comparison of β-amyloid 40 levels in 

















































Figure 2-53: SUMMIT T2DM cohort - comparison of β-amyloid 40 levels in 
subjects without and with incretin use, n=359, n=36 respectively. 
Figure 2-54: SUMMIT T2DM cohort - comparison of β-amyloid 40 levels in 
subjects without and with insulin use, n=302, n=92 respectively. 
Figure 2-55: SUMMIT T2DM cohort - comparison of β-amyloid 40 levels in 

















































Figure 2-56: SUMMIT T2DM cohort - comparison of β-amyloid 40 levels in subjects 
without and with statin use, n=73, n=324 respectively. 
Figure 2-57: SUMMIT T2DM cohort - comparison of β-amyloid 40 levels in subjects 
without and with sulphonylurea use, n=266, n=131 respectively. 
Figure 2-58: SUMMIT T2DM cohort - comparison of β-amyloid 42 levels in subjects 


















































Figure 2-59: SUMMIT T2DM cohort - comparison of β-amyloid 42 levels in female 
and male subjects, n=127, n=258 respectively. 
Figure 2-60: SUMMIT T2DM cohort - comparison of β-amyloid 42 levels in 
subjects without and with ACE inhibitor use, n=204, n=193. 
Figure 2-61: SUMMIT T2DM cohort - comparison of β-amyloid 42 levels in subjects 















































Figure 2-62: SUMMIT T2DM cohort - comparison of β-amyloid 42 levels in subjects 
without and with β-blocker use, n=271, n=124 respectively. 
Figure 2-63: SUMMIT T2DM cohort - comparison of β-amyloid 42 levels in 
subjects without and with biguanide use, n=117, n=281 respectively. 
Figure 2-64: SUMMIT T2DM cohort - comparison of β-amyloid 42 levels in subjects 


















































Figure 2-65: SUMMIT T2DM cohort - comparison of β-amyloid 42 levels in 
subjects without and with DPP-4 Inhibitor use, n=368, n=26 respectively. 
Figure 2-66: SUMMIT T2DM cohort - comparison of β-amyloid 42 levels in 
subjects without and with diuretic use, n=266, n=129 respectively. 
Figure 2-67: SUMMIT T2DM cohort - comparison of β-amyloid 42 levels in subjects 
















































Figure 2-68: SUMMIT T2DM cohort - comparison of β-amyloid 42 levels in 
subjects without and with glitazone use, n=369, n=25 respectively. 
Figure 2-69: SUMMIT T2DM cohort - comparison of β-amyloid 42 levels in 
subjects without and with incretin use, n=360, n=36 respectively. 
Figure 2-70: SUMMIT T2DM cohort - comparison of β-amyloid 42 levels in 
















































Figure 2-71: SUMMIT T2DM cohort - comparison of β-amyloid 42 levels in 
subjects without and with nitrite use, n=331, n=63 respectively. 
Figure 2-72: SUMMIT T2DM cohort - comparison of β-amyloid 42 levels in 
subjects without and with statin use, n=73, n=324 respectively. 
Figure 2-73: SUMMIT T2DM cohort - comparison of β-amyloid 42 levels in 



















































The above analysis looked at binary determinants of β-amyloid 40 and 42, including 
the use glucose lowering agents. Significant differences in plasma β-amyloid 40 
levels were found when dividing subjects based ARB use, diuretic use and insulin 
use. When looking at β-amyloid 42, significant differences were found when dividing 
subjects based on diuretic use and insulin use.  
 
 Regression Analysis of Independent Determinants of β-amyloid – SUMMIT 
T2DM Cohort 
 
In order to determine which factors are independently associated with plasma β-
amyloid levels in diabetic subjects, a linear regression model was used. The standard 
threshold for significance (p<0.05) was used to select factors to be included in the 
model, as the linear regression method adjusts for multiple comparisons Significant 
variables identified from the analyses above were entered into the model and 
selected using forward selection.. B refers to the unstandardized regression 
coefficient which represents the slope of the model associated with a 1 unit change 
in the independent variable. Βeta refers to the standardised regression coefficient 
and allows for direct comparison of the effects of independent variables.  
 
Table 2-6: Linear regression model with and independent variables Age, Height, Total 
cholesterol, LDL Cholesterol, eGFR, Insulin use, Diuretic use, ARB use selected using 
forward selection – SUMMIT T2DM cohort. 
β-amyloid 40 
Independent Variables B Beta Sig.  
Insulin Use 47.089 0.195 3.35E-4 
eGFR (mL/min/1.73 m²) -0.780 0.180 0.001 
Diuretic Use 28.906 0.135 0.013 
 
 
Table 2-7: Linear regression model with and independent variables Age, Height, LDL 
cholesterol, Insulin use, Glitazone use, Diuretic use, ARB use selected using forward 
selection – SUMMIT T2DM cohort. 
β-amyloid 42 
Independent Variables B Beta Sig.  
eGFR (mL/min/1.73 m²) -0.064 -0.266 5.99E-7 




Based on this analysis, it would appear that insulin use, eGFR and diuretic use are 
the only significant factors independently associated with plasma β-amyloid 40 in 
the T2DM cohort. For beta amyloid 42, eGFR and insulin use were found to be 
independent significant determinants.  
 Subgroup Analysis: SUMMIT No T2DM cohort 
 
The same analysis was then carried out in subjects without T2DM. Pearson or 
Spearman correlation was used depending on variable distribution. As before, the 
Bonferroni correction was used to take into account multiple comparisons, with 
p<0.003 as the new accepted threshold for statistical significance. Scatter plots of 
significant correlations are displayed below.  
 
Table 2-8: Correlations of plasma β-amyloid with continuous baseline characteristics in 
the SUMMIT non-T2DM cohort. 
 Spearman's Rho Aβ40 Aβ42 
Age (years) Correlation Coefficient 0.281 0.115 
 Sig. 8.0E-06 0.073 
 N 243 243 
Body Mass Index (kg/m2) Correlation Coefficient 0.046 -0.048 
 Sig. 0.48 0.454 
 N 243 243 
Height (m) Correlation Coefficient -0.222 -0.122 
 Sig. 4.8E-04 0.058 
 N 244 244 
Weight (kg) Correlation Coefficient -0.109 -0.127 
 Sig. 0.09 0.048 
 N 244 244 
HbA1c (mmol/mol) Correlation Coefficient 0.093 0.072 
 Sig. 0.149 0.269 
 N 241 241 
Total Cholesterol 
(mmol/l) 
Correlation Coefficient -0.049 -0.111 
 Sig. 0.449 0.088 
 N 239 239 
LDL Cholesterol (mmol/l) Correlation Coefficient -0.049 -0.151 
 Sig. 0.463 0.024 
 N 225 225 
HDL Cholesterol (mmol/l) Correlation Coefficient -0.016 0.07 
 Sig. 0.809 0.286 
 N 236 236 
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Triglycerides (mmol/l) Correlation Coefficient 0.007 -0.031 
 Sig. 0.918 0.633 
 N 235 235 
eGFR (mL/min/1.73 m²) Correlation Coefficient -0.303 -0.315 
 Sig. 2.0E-06 7.65E-07 









































Figure 2-74: Scatter plot of age with β-amyloid 40 – SUMMIT no T2DM cohort. 
n=243, r=0.281, p=8.0E-6. 
Figure 2-75: Scatter plot of height with β-amyloid 40 – SUMMIT no T2DM 




































The above analysis looked at univariate correlations between plasma β-amyloid and 
continuous clinical determinants in SUMMIT subjects without T2DM. After adjusting 
for multiple comparisons, a significant positive correlation was seen between β-
amyloid 40 and age, while significant negative correlations were present between β-
amyloid 40 and height as well as eGFR. After the Bonferroni correction, the only 






Figure 2-76: Scatter plot of eGFR with β-amyloid 40 – SUMMIT no 
T2DM cohort. n=237, r=-0.303, p=2.0E-6. 
Figure 2-77:  Scatterplot of eGFR with β-amyloid 42 – SUMMIT no T2DM 
cohort. n=237, r=-0.315, p=7.65E-7. 
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Figure 2-78: SUMMIT Non-T2DM cohort - comparison of β-amyloid 40 levels 
in subjects without and with CVD, n=120, n=124 respectively. 
Figure 2-79: SUMMIT Non-T2DM cohort - comparison of β-amyloid 40 levels 
in females and males, n=96, n=147 respectively. 
 Association of Plasma β-amyloid with Binary Determinants: SUMMIT No 
T2DM Cohort 
 
To analyse the association of different pharmacological agents, gender and CVD 
status with plasma β-amyloid in the non-diabetic cohort, new plasma β-amyloid 
quartiles were calculated using only the values of non-diabetic subjects. To adjust for 








































Figure 2-80: SUMMIT Non-T2DM cohort - comparison of β-amyloid 40 levels in 
subjects without and with ACE inhibitor use, n=180, n=62 respectively. 
Figure 2-81: SUMMIT Non-T2DM cohort - comparison of β-amyloid 40 in subjects 
without and with angiotensin II receptor blocker use, n=218, n=24 respectively. 
Figure 2-82: SUMMIT Non-T2DM cohort - comparison of β-amyloid 40 levels 















































Figure 2-83: SUMMIT Non-T2DM cohort - comparison of β-amyloid 40 levels in 
subjects without and with calcium channel blocker use, n=199, n=43 respectively. 
Figure 2-84: SUMMIT Non-T2DM cohort - comparison of β-amyloid 40 levels 
in subjects without and with diuretic use, n=213, n=29 respectively. 
Figure 2-85: SUMMIT Non-T2DM cohort - comparison of β-amyloid 40 levels 


















































Figure 2-87: SUMMIT Non-T2DM cohort - comparison of β-amyloid 42 levels in 
subjects without and with CVD, n=120, n=124 respectively. 
Figure 2-88: SUMMIT Non-T2DM cohort - comparison of β-amyloid 42 levels in 
































Figure 2-86: SUMMIT Non-T2DM cohort - comparison of β-amyloid 40 levels in 
subjects without and with statin use, n=113, n=128 respectively. 
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Figure 2-89: SUMMIT Non-T2DM cohort - comparison of β-amyloid 42 levels in 
subjects without and with ACE inhibitor use, n=180, n=62 respectively. 
Figure 2-90: SUMMIT Non-T2DM cohort - comparison of β-amyloid 42 levels in subjects 
without and with angiotensin II receptor blocker use, n=219, n=23 respectively. 
Figure 2-91: SUMMIT Non-T2DM cohort - comparison of β-amyloid 42 levels 













































Figure 2-92: SUMMIT Non-T2DM cohort - comparison of β-amyloid 42 levels in 
subjects without and with calcium channel blocker use, n=199, n=43 respectively. 
Figure 2-93: SUMMIT Non-T2DM cohort - comparison of β-amyloid 42 levels in 
subjects without and with diuretic use, n=213, n=29 respectively. 
Figure 2-94: SUMMIT Non-T2DM cohort - comparison of β-amyloid 42 levels 

















































Figure 2-95: SUMMIT Non-T2DM cohort - comparison of β-amyloid 42 


















The above analysis looked at potential binary determinants of plasma β-amyloid in 
SUMMIT subjects without T2DM. After setting the new threshold for significance at 





























 Regression Analysis of Independent Determinants of β-amyloid – SUMMIT 
No T2DM Cohort 
 
In order to determine which factors are independent predictors of plasma β-amyloid 
in subjects without T2DM, a linear regression model was used. Significant variables 
identified from the univariate analyses above were entered into the model and 
selected using forward selection. As previously, the standard level of significance 
p<0.05 was used to select factors to be included in the regression.  B refers to the 
unstandardized regression coefficient which represents the slope of the model 
associated with a 1 unit change in the independent variable. Beta refers to the 
standardised regression coefficient and allows for direct comparison of the effects of 
independent variables.  
 
 
Table 2-9: Linear regression model with independent variables Age, BMI, Height and eGFR 









Table 2-10: Linear regression model with independent variables Weight, LDL cholesterol, 
eGFR, Statin use selected using forward selection 
β-amyloid 42 
Independent Variables B Beta Sig.  
eGFR (mL/min/1.73 m²) -0.095 -0.345 1.46E-07 
 
As can be seen from the above regression analysis, eGFR, age and height were the 
only significant independent associations with β-amyloid 40. eGFR was the only 







Independent Variables B Beta Sig.  
eGFR (mL/min/1.73 m²) -1.205 -0.263 3.00E-05 
Age (years) 1.68 0.187 0.003 





The development of assays capable of measuring plasma β-amyloid was followed by 
excitement surrounding its potential use as a biomarker of AD. Disappointingly 
however, several studies have reliably shown that plasma β-amyloid is a poor 
predictor of the development or progression of AD (63). The above analysis perhaps 
sheds some light on the reasons behind its failure as a biomarker in this condition, as 
it suggests that plasma β-amyloid is potentially affected by a large number of patient 
characteristics and is also influenced by pharmacological agents.  This study is the 
first of its kind to extensively look at determinants of plasma β-amyloid 40 and 42 in 
non-elderly subjects.  
 
 Plasma β-amyloid and Renal Function 
 
The most significant association of plasma β-amyloid is estimated glomerular 
filtration rate, a surrogate marker of renal filtration function calculated on the basis 
of creatinine concentrations, a molecule filtered but poorly secreted and poorly 
absorbed by renal tubular cells. A strong inverse relationship between plasma β-
amyloid and renal function has previously been reported by a number of studies 
(56,64). However, several gaps in our knowledge remain. Firstly, it remains to be 
determined whether free circulating β-amyloid is primarily renally excreted and 
therefore found to accumulate in subjects with declining renal function, or whether 
increased free circulating β-amyloid is nephrotoxic and results in a decline in renal 
function. If declining renal function is found to cause accumulation of free circulating 
plasma β-amyloid the possible causal mechanisms are plentiful. Being only 4kDa in 
size, it is possible that free circulating β-amyloid is simply filtered at the glomerulus 
and excreted in the urine. Indeed, despite the paradigm of a healthy glomerulus 
being impermeable to protein, it is now recognised that the filtration of smaller 
peptides as well as larger proteins at the glomerulus occurs even in the healthy state 
and is dictated primarily by peptide charge and size as well as glomerular slit size 
(65,66).  
Another possible explanation takes into account other important processes carried 
out at nephron level including metabolism of various substrates. It is well known that 
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insulin is degraded at least in part by the kidneys (67,68). Therefore, it is possible 
that should β-amyloid prove to be a biomarker of CVD, it could simply be acting as a 
biomarker of renal function, with poor renal function being the underlying causal 
association 
 
 Plasma β-amyloid and Pharmacological Agents 
 
As reviewed previously in the introduction, a small number of studies looking at the 
association between plasma β-amyloid and pharmacological agents exist. The 
findings in the present study reproduce some of the results presented previously. In 
agreement with previous findings, higher plasma β-amyloid 42 levels were 
significantly associated with insulin use in subjects with type 2 diabetes. A number of 
studies have previously reported an association between β-amyloid and insulin. 
Plasma β-amyloid was shown to correlate with levels of endogenous insulin (69). 
Additionally, administration of exogenous insulin was also shown to increase levels 
of circulating β-amyloid 42 (70). However, the reasons behind this association 
remain poorly understood. When looking at univariate analyses, higher plasma β-
amyloid levels were consistently associated with presence of T2DM. Therefore, it is 
possible that the association between insulin use and plasma β-amyloid is simply a 
reflection of a longer duration of T2DM.  
No significant relationship was found with plasma β-amyloid and NSAIDs or statins. 
An interesting finding is that in univariate analyses, plasma β-amyloid levels were 
significantly higher in subjects on angiotensin II receptor blockers but not ACE 
inhibitors. However, use of ARBs was not found to be independently associated with 
plasma β-amyloid levels in regression analyses.  
Another interesting observation that remained statistically significant even in 
regression analysis, is the association of plasma β-amyloid with diuretic use. In both 
the SUMMIT cohort and the SUMMIT T2DM cohort, the use of diuretics was 
associated with an approximately 30pg/ml increase in plasma β-amyloid 40 levels. 
Unfortunately, information about use of specific types of diuretics was lacking in the 
database. Given that different types of diuretics function in different ways it is 
therefore difficult to try and speculate about potential mechanisms behind this 
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association. However, generic properties of most diuretics include inducing diuresis 
by means of natriuresis, with variable effects on other electrolytes. Although 
diuretics have been in widespread clinical use for decades and their molecular effect 
on the nephron is well understood, the effect of diuretics on eGFR is unknown. A 
small number of human studies have yielded conflicting results. Loon et al found 
that administration of furosemide to 9 hypertensive subjects with normal renal 
function resulted in a non-significant increase in eGFR, while Gottlieb et al found a 
decrease in eGFR of 12 subjects with congestive heart failure after administration of 
furosemide (71,72). Trivedi also concluded that acutely, administration of 
Furosemide results in a reduction in eGFR (73). Therefore, it is difficult to determine 
whether an increase in plasma β-amyloid in subjects on diuretics is due to their 
effects on eGFR.  
 
 Outliers in plasma β-amyloid and other clinical variables 
 
As is evident from the preceding analysis, a number of outliers can be seen when 
looking at levels of plasma β-amyloid 40 and 42 as well as other baseline clinical 
parameters. 21 subjects were found to have low plasma β-amyloid 40 levels while 19 
subjects were found to have low β-amyloid 42 levels. In an attempt to determine the 
reason behind this observation, we considered a number of different possible 
explanations. Firstly, we looked at the possibility of assay failure. However, the 
samples corresponding to low values of plasma β-amyloid 40 and 42 were scattered 
across a number of different assay plates and therefore assay failure was deemed 
unlikely. Another potential explanation is that a qualitative issue with the sample 
resulted in the degradation of our peptide of interest. However, all samples were 
stored under the same conditions and no significant abnormalities were seen when 
looking at other baseline biological plasma markers measured in the same sample. 
Additionally, we also found that although the values reported for some subjects 
were extremely low, they were still well within the minimum detection limit for the 
assay used to measure plasma β-amyloid concentrations. An interesting observation 
is that all of the samples with low levels of plasma β-amyloid are from subjects 
within the Exeter cohort. Therefore, it is possible that unknown biological and 
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genetic factors are responsible for this phenomenon. However, these cannot be 
reliably adjusted for.  A possible solution in the future would be to perform an 
analysis of subjects recruited in the Exeter and Dundee cohorts separately, in an 
attempt to take into account unknown confounders and differences among the 
groups. This would also allow one to take into account the effects of different 
medication prescribing behaviours in different geographical areas within the UK.  
Other outliers were identified when looking at the baseline parameters of eGFR as 
well as LDL cholesterol. However, no clear explanation for such low values could be 
determined based on the data available. Therefore, all of the outliers discussed 
above were included in the analysis. 
 Limitations of Study 
 
There are a number of limitations of this exploration of factors affecting plasma β-
amyloid levels. Firstly, due to limited amounts of blood samples from subjects 
enrolled in the study, plasma β-amyloid was only measured as a one-off 
measurement in all of the samples. Therefore, any assay faults or poor quality of 
individual specimens cannot be accounted for.  Another limitation directly related to 
only analysis one-off measurements of plasma β-amyloid is the fact that the effects 
of circadian variation cannot be accounted for. As with a number of circulating 
molecules, the natural circadian rhythm often exerts a considerable effect on their 
plasma concentrations. The most extreme example of this would be cortisol, where 
diurnal variations in plasma concentrations result in as much as a 50% increase in its 
concentrations shortly after awakening (74). Indeed, the results of one small study 
would suggest that plasma β-amyloid levels demonstrate variation based on 
circadian rhythms and that the amplitude of these variations diminishes with age 
(75). In the SUMMIT database, attempts were made at adjusting for circadian 
variation by wherever possible, recording measurements and collecting blood 
samples in the morning.  
 
Yet another factor that could hinder attempts at investigating associations with 
circulating β-amyloid, is that in healthy humans, approximately 70% of β-amyloid 40 
81 
 
and 90% of β-amyloid 42 circulates in the bound form (76). Assays used to measure 
plasma β-amyloid measure only the free circulating form. As with other protein 
bound plasma molecules, changing between protein bound and free circulating 
forms is a dynamic process. Currently, factors affecting transitioning between 
protein bound and free circulating β-amyloid are unknown.  
 
In terms of the analysis of pharmacological agents with plasma β-amyloid 
concentrations, a major limitation is the lack of information about specific 
medication types. Although the database provides information about the use of 
broad categories of medications such as diuretics, statins or NSAIDs, information 
about specific preparations is lacking. This is potentially significant, as a previous 
study found differing effects of different NSAID preparations on plasma β-amyloid 
levels. Additionally, given the strong association between diuretic use and plasma β-
amyloid levels, a possible mechanistic explanation for this cannot be provided. This is 
because different classes of diuretics function via a number of different mechanisms.  
 
Another major limitation of this study is the relatively imbalanced size of subgroups. 
There is a larger number of subjects in the diabetic cohorts compared to the non-
diabetic cohorts. When performing an analysis of the baseline cohort, this may 
therefore skew the results towards a more diabetic phenotype. Indeed, it would 
seem that on a number of occasions, results seen in the baseline cohort are more 
closely related to those observed in the diabetic cohort. However, regression 
analysis of the SUMMIT cohort adjusted for diabetes status, therefore, this would 
likely resolve the issue of imbalanced groups.  Another potential explanation for this 
observation is statistical power. Given that the non-diabetic subgroup will be 
statistically underpowered when compared to the diabetic subgroup, it is possible 
that the number of subjects simply diminishes the significance of any associations. 
The pre-existing database used in this study was not one specifically designed for the 
purpose of the above analyses, and therefore it was impossible to attempt to control 




 Future Directions 
 
Despite a large number of drawbacks, this study provides valuable, novel 
information about the factors affecting plasma β-amyloid concentrations and 
highlights a number of interesting associations that could be the subject of future 
research. Firstly, it would be of great interest to look at plasma β-amyloid levels in 
relation to some of the above factors in a new, purpose-designed study which would 
allow one to account for factors such as circadian variability. Additionally, further 
studies aiming to tease apart the mechanisms explaining the association between 
plasma β-amyloid and use of diuretic/ renal function would be of potential 





















3 Association of plasma β-amyloid with biomarkers of 
cardiovascular health and cardiovascular outcomes 
 
 Assessing Vascular Health in the Research Setting 
 
As discussed in chapter 1, biomarkers of CVD currently in use have a number of 
limitations and struggle to identify a significant number of subjects at risk of major 
cardiovascular events. Therefore, the search for potential novel biomarkers 
continues to be important. Ideally, any novel biomarkers should be directly involved 
in the pathophysiological pathways in the disease of interest or should provide an 
accurate representation of the extent or severity of the pre-clinical stages of the 
disease. In the context of CVD, a number of methods are commonly used in the 
research setting to assess either structural or functional components of 
cardiovascular health and therefore provide a means of quantifying the extent or 
severity of pre-clinical stages of CVD. Therefore, by demonstrating an association 
between any potential novel biomarkers of CVD and pre-clinical functional/ 
structural changes in the vasculature, one can not only prove the usefulness of a 
novel biomarker in estimating pre-clinical disease extent, but hopefully also shed 
some light on the potential mechanisms behind any associations. Although plentiful 
methods for assessing vascular health in the research setting exist (see Table 3.1), 



















Table 3-1: Summary of methods used for functional and structural assessment of the vascular tree in the research setting 






Microcirculation - Forearm 
circulation with brachial 
artery drug administration 
Reproducible, 
contralateral limb as 
control, readily accessible 
vascular bed 
Invasive, potential 
damage to brachial 
artery, lack of 
outcome studies 







dilatation (78) Brachial artery 
Easily accessible vascular 










Laser Doppler ± 
iontophoresis (80) Skin microcirculation 
Non-invasive, no observer 
dependency  





hyperaemia  (81,82) 
EndoPAT (83)  Digital microcirculation 
Non-invasive, FDA 
approved, automated so 




hyperaemia  (84,85) 
Pulse wave 
analysis/velocity 
(86) Global vascular assessment 
Non-invasive, extensive 
evidence base for CVD 
outcomes 
Uncertainty of true 
path length - obesity NA  (87–89) 
Ankle-brachial 
pressure index (90) Global vascular assessment 
Non-invasive, readily 
available in clinical areas 
Observer dependency, 
less useful in subjects 
with calcification NA  (91,92) 
Carotid Intima-
Media Thickness 







coronary circulation NA (94,95) 
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 Functional Assessment  
 
Once considered only a simple layer of cells with little function, the endothelium is 
now recognised as an important regulator of vascular homeostasis. Indeed, 
endothelial dysfunction or activation in response to a range of different stimuli is 
thought to be the first step in the development of atherosclerosis, long preceding 
the onset of structural changes. The idea that atherosclerosis was not solely a 
structural problem was first introduced in 1986 by Ludmer et al. Using intracoronary 
infusions of acetylcholine (ACh) combined with quantitative angiography they 
demonstrated that atherosclerosis in the coronary arteries was as much a structural 
as it was a functional defect (96). Since then, several safer and less invasive methods 
have been developed to measure endothelial function and these have consistently 




EndoPAT is a non-invasive device designed to record beat-beat changes in pulse 
wave amplitude in the digital circulation. A probe is placed on the finger, and 
baseline recordings are measured. A blood pressure cuff is then inflated to above 
systolic pressure in order to occlude the circulation to the hand. After 5 minutes, the 
cuff is released and changes in pulse wave amplitude are compared to baseline (83) 













Figure 3-1: Diagram depicting set up for measurement of the reactive 
























This method of measuring endothelial function has several advantages including its 
non-invasive nature, a fully automated procedure, the ability of the contralateral 
arm to serve as a control for any systemic changes in vascular tone as well as 
approval from the Food and Drug Administration (FDA), USA as a measure of 
endothelial function. However, a major limitation is the cost of the single-use finger 
probes. Critics of this method also highlight, that the digital circulation is perhaps not 
the most useful vascular bed for measuring endothelial function, as it is highly 
sensitive to a range of different factors including temperature and state of the 
autonomic nervous system (98). 
 
 Laser Doppler and Skin Microcirculation  
 
Another method used to functionally assess the endothelium is the use of laser 
Doppler on the skin microcirculation in combination with iontophoresis of vasoactive 
drugs, reactive hyperaemia or heating. This form of vascular function assessment 
takes advantage of the Doppler effect, whereby light via a low power laser 
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illuminates the skin and undergoes a shift in frequency proportional to the velocity 
of red blood cells within the skin vasculature. (See Figure 3-2)  
 
 
Figure 3-2: Using the Doppler effect to measure endothelial function in the skin 
microcirculation. A helium-neon laser can penetrate skin layers through to the dermis up 
to a depth of approximately 1.5mm. Image from  (99) 
 
Originally, 2 methods utilising this effect were available. Laser Doppler flowmetry 
analyses blood flow in a small area but with a high sampling frequency. It therefore 
has very good temporal resolution but poor spatial resolution, which, given the 
heterogeneity in skin perfusion is a potential limitation and accounts for poor 
reproducibility as a one-off measurement of baseline (80). Laser Doppler imaging on 
the contrary provides better spatial resolution, but has a low sampling frequency 
and is therefore relatively insensitive to rapid changes in skin perfusion (80). 
However, laser Doppler imaging can be combined with iontophoresis of vasoactive 
substances such as ACh, whereby a small a current (μA) drives charged molecules of 
vasoactive drugs across the skin. Whilst it is not the method of choice for assessing 
dynamic changes in blood flow, with serial measurements at different doses this set 
up allows for the generation of a dose response curve and thus quantifies the ability 
of the endothelium to respond adequately to a given stimulus. To further increase 
the speed of image acquisition, several groups have optimised the protocol with 
changes such as reducing the size of the area to be scanned or increasing the 
scanning speed (80). A further advantage of this method is that depending on the 
vasoactive substance applied, either endothelium dependent or independent 
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Figure 3-3: (A, B) Iontophoresis chambers used for drug delivery on subject’s 
forearm. The polarity of chambers can be altered depending on the charge 
(positive or negative) of drug in solution. Image from (80) 
vasodilation can be assessed. When ACh is used it binds to M3 muscarinic receptors 
on endothelial cells and leads, in part, to the endothelial production of nitric oxide 
(NO) (in addition prostacyclin and endothelium-derived hyperpolarising factor) thus 
measuring an endothelium-dependent form of vasodilation. Sodium nitroprusside 
(SNP) on the other hand acts as a direct NO donor, and thus by-passes the 
endothelial component acting directly on vascular smooth muscle cells (VSMC). 
Other stimuli that can be applied to the vascular bed and have their response 
measured using this method include vascular perfusion response to a heat stimulus 





















To combat the limitations of both laser Doppler imaging and laser Doppler 
flowmetry, a newer technology, laser speckle contrast imaging has been developed 









Clearly, this field is of great interest as the use of the skin microcirculation as a 
surrogate marker of general vascular health provides many advantages. Not only is it 
an easily accessible and non-invasive method of assessment, but studies have shown 
a significant positive correlation between skin microvascular function assessed by 
means of laser Doppler imaging and ACh/SNP iontophoresis and measures of 
coronary vascular function (101).   
 
 
 Structural Assessment: 
 
Functional assessment of the endothelium allows detection of early, pre-clinical 
disease prior to the formation of structural changes. As such, these techniques are 
less useful for measuring atherosclerotic disease burden in established 
atherosclerosis. Several methods looking at vascular structure as opposed to 






Figure 3-5: Carotid intima media thickness is measured as the distance between the 
lumen-intima boundary (in yellow) and the intima-media boundary (in pink). Figure 
from (102,103) 
 Carotid Intima-Media Thickness 
 
One commonly used structural arterial test is measurement of carotid intima media 
thickness (IMT). The common carotid (CC) arteries terminate at the carotid bulb, 
which divides to form the internal and external carotid artery (see figure 3.5  - 























Using ultrasound, the distance between the intima-lumen interface and media-
adventitia interface is measured in multiple segments along the course of the CC 
arteries. Studies have shown that a 0.2mm increase in carotid intima media 
thickness is associated with a 33% increase in risk of myocardial infarction and a 28% 
increase in risk of stroke (104). Additionally, on the contrary to commonly used 
cardiovascular risk scores, determining risk based on carotid intima thickness takes 
into account the effects of risk modifying agents such as statins. Indeed, a 
randomised meta-analysis of randomised controlled trials concluded that statin 
therapy was associated with a favourable decrease in CC artery IMT (105). Other 
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useful information that can be obtained using this method is assessment of plaque 
size and stability (105). 
 Assessment of Arterial Stiffness – Pulse Wave Velocity and Augmentation 
Index 
 
The arterial tree has 2 distinct functions – a conduit function ensuring tissue 
perfusion and the cushioning functioning. This serves to transform a pulsatile flow 
generated by myocardial contraction into a continuous flow and also dampens down 
individual fluctuations in blood pressure. The ability of the arterial system to 
adequately perform these functions is in part dictated by arterial stiffness. Upon 
ventricular contraction, a forward pressure wave is generated which is reflected at 
different parts of the arterial tree and travels back as the reflected pressure wave. 
When arteries are compliant, the timing of the reflected pressure wave is such that it 
reaches the central arteries during late systole/early diastole, thus contributing to 
diastolic pressure (DBP) and coronary perfusion. However, when arterial stiffness 
increases, the velocity of the incident as well as reflected pressure wave increases 
and the reflected wave arrives back within central arteries at an earlier point in the 
cardiac cycle (107). It is precisely this mechanism that is responsible for the 
phenomenon of increased pulse pressure in elderly individuals, whereby an early, 
reflected wave joins the incident pressure wave causing an increased systolic 
pressure, but reduced DBP. The amount by which the early reflected pressure wave 
alters the normal central pressure waveform is measured as the augmentation index 
(AI) (see figure 3-6, diagram from (108)). Understandably, due to the normal 
physiology of coronary perfusion, preload and afterload, this phenomenon therefore 













Figure 3-6: Diagram of pulse waveforms seen in central arteries of different stiffness. 
P1= peak of the incident wave. P2 = peak of the reflected wave. Figure from (108)  



















A commonly used device to measure pulse wave velocity is the SphygmoCor system. 
According to the manufacturer’s protocol, the subject is to be placed supine and 
resting for at least 5 minutes. A thigh cuff is placed as far up the thigh as possible 
and the carotid pulse is then located on the neck. The cuff placed around the thigh 
records femoral waveform data whilst a hand-held tonometer records the waveform 
in the carotid artery (see figure 3-7, image from (109)). Distances between the cuff, 
sternal notch, femoral pulse and carotid pulse, allows the software to calculate the 
transit time from carotid to femoral artery to give the pulse wave velocity. Whilst 
radial:carotid transit times can also be measured, carotid to femoral measurements 















Although a completely non-invasive and relatively fast method for measuring arterial 
stiffness, a major disadvantage is the requirement for extensive operator training, as 
obtaining good quality, reproducible waveform tracings for at least 10 seconds can 
be challenging. Another major challenge is that in addition to the SphygmoCor 
system described above, other devices for measuring pulse wave velocity exist, such 
as the Arteriograph and Complior systems. Studies have shown that these systems 
produce significantly different results and values obtained using different systems 
therefore cannot be directly compared (111). However, measurement of pulse wave 
velocity in the research setting is of value as it has been extensively validated and 
shown to predict cardiovascular outcomes in a number of large studies. A meta-
analysis by Vlachopolous et al. looked at 17 longitudinal studies measuring aortic 
pulse wave velocity. They report a stepwise, linear increase in clinical events with 
increasing pulse wave velocity tertiles, but note that arterial stiffness was the 
strongest predictor of cardiovascular outcomes in individuals with a higher baseline 
risk (88). Among patients with diabetes, several studies have shown that arterial 
stiffness is related to the progression of cardiovascular complications, whilst other 
studies have shown that changes in arterial stiffness occur even in the pre-diabetic 
stages (112).  
 
 
 β-amyloid and cardiovascular disease 
 
As mentioned in the previous chapter, β-amyloid is a peptide investigated primarily 
in the context of AD and CAA. Indeed, plasma β-amyloid was not one of the main 
biomarkers initially measured in the SUMMIT database, and was only measured 
retrospectively in a subset of the dataset on the background of interesting findings 
from a mouse study by Meakin et al. (33). By retrospectively measuring β-amyloid 
levels in samples from a pre-existing cardiovascular database, the current 
translational follow up MSc project allows for the investigation of previous findings 
in the human population. The following review will aim to summarise our current 
knowledge of β-amyloid in the context of CVD processes.  
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 Animal Studies  
 
Many early hypotheses suggested that AD was caused by atherosclerosis of the 
cerebral vasculature. While this hypothesis is no longer widely accepted, a link 
between, β-amyloid levels and vascular dysfunction persists with a considerable 
evidence base from experimental animal models. Van De Parre et al. used the 
atherosclerosis-prone ApoE knockout mice (ApoE -/- ) and ApoE-/- APP-/- mice and 
found that after feeding with a high-fat diet, atherosclerotic plaque size was 
significantly reduced in thoracic and abdominal aorta regions in APP -/- mice. They 
also report that ApoE-/- APP-/- mice have greater plaque stability (113). 
Other studies have shown that β-amyloid has direct vasoactive properties. One study 
looked at transgenic mice over-expressing APP, and found that following 
somatosensory stimulation, mice over-expressing APP had significantly smaller 
increases in cerebral blood flow. Additionally, impaired cortical blood flow was 
shown to correlate with β-amyloid levels in the brain and was also reproduced in 
wild type mice after topical administration of β-amyloid 40 (114). Other studies have 
shown that β-amyloid mediated changes in vasomotor tone occur in an 
endothelium-dependent manner. Dietrich et al. looked at adenosine triphosphate 
(ATP)-induced vessel constriction in rat arterioles after administration of β-amyloid. 
Both β-amyloid 40 and β-amyloid 42 were shown to result in a significant reduction 
in the vasodilator response to ATP administration (32). More recently, the role of β-
amyloid has also been looked at in the systemic vasculature. Preliminary data from 
our group showed that BACE1 staining was increased in human temporal arteries 
with atherosclerosis. Additionally, increasing levels of β-amyloid in mice over a 
longer period of time via infusion of mouse β-amyloid caused a significant reduction 
in the vasodilator response of the skin microcirculation to ACh iontophoresis when 
compared to mice infused with a scrambled β-amyloid peptide. Treatment of high 
fat diet fed mice with the BACE1 inhibitor Merck-3 improved vascular responsiveness 





Figure 3-8: Unpublished results by Meakin et al – effect of β-amyloid on vascular 















 β-amyloid and cardiovascular disease: Evidence from human studies 
 
Several studies have also looked at β-amyloid in relation to human vascular health in 
vivo. Beach et al. analysed the severity of atherosclerosis in the circle of Willis in 215 
subjects with AD, 30 subjects with vascular dementia and 92 subjects without any 
form of dementia. Subjects with AD were found to have more advanced 
atherosclerosis than subjects in other groups (116). One small-scale study 
demonstrated a relationship between increased β-amyloid deposition within the 
brain and higher systolic blood pressure as well as pulse pressure in healthy, middle-
aged individuals. Due to increased pulse pressure values, they postulated that this 
was likely due to changes in arterial stiffness (117). To follow this up, Hughes et al. 
used positron emission tomography scans to quantify β-amyloid deposition in the 
brains of 81 non-demented individuals and found that greater brachial-ankle pulse 
wave velocity was associated with higher levels of β-amyloid deposition in the brain 
at both baseline and 2 year follow up. However, carotid-femoral pulse wave velocity 
was not significantly increased in those with higher β-amyloid deposition in the brain 
(118).  
Whilst understandably the majority of research thus far has focused on β-amyloid 
levels within the brain, some more recent studies have looked at link between 
circulating β-amyloid and vascular health. Stamatelopoulos et al. retrospectively 
measured β-amyloid 40 in blood samples from patients previously enrolled in other 
cardiovascular studies and found that circulating β-amyloid 40 was an independent 
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predictor of death and major adverse cardiac events in patients with coronary heart 
disease. After measuring pulse wave velocity at both baseline and at a median 4.4 
years of follow up, increased β-amyloid 40 levels were also independently associated 





Clearly, there is evidence that β-amyloid is a potential, but relatively unexplored risk 
factor in CVD. However, more research is required to tease apart this relationship 
and to better understand the role of other β-amyloid peptides, the relationship with 
diabetes as well as other markers of vascular health and pre-clinical atherosclerosis.  
The following analysis will aim explore the relationship between circulating β-
amyloid and functional and structural biomarkers of cardiovascular health described 
above, as well as its association with CVD and outcomes. Additionally, this analysis 
will aim to determine whether any associations of plasma β-amyloid with biomarkers 
of cardiovascular health or cardiovascular outcome differs between subjects with or 




Based on evidence from our previous animal study, it is hypothesised that plasma β-
amyloid will be primarily associated with functional vascular changes and that higher 
β-amyloid levels will be associated with impaired endothelium dependent functional 
responses to stimuli. Based on evidence from previous human studies reviewed 
above, it is also hypothesised that higher plasma β-amyloid 40 levels will associate 
with impaired arterial stiffness as well as impaired endothelium-independent 
functional responses to stimuli. 
 
 Methods 
 Study Population:  
 





 Structural and Functional Vascular Measurements  
 
The following techniques for functional and structural vascular assessment had been 
previously used in the pre-existing SUMMIT database:  
1. EndoPAT – Reactive Hyperaemia index 
2. Arterial stiffness using the SphygmoCor device– pulse wave velocity 
3. Ultrasound measurement of carotid intima-media thickness (cIMT) – left and 
right-sided common carotid IMT, left and right-sided common carotid bulb 
IMT 
4. Laser Doppler Iontophoresis – Reactive hyperaemia peak response, SNP peak 
response, ACh peak response 
 
More details about the exact methodology for each of the above vascular 
measurements can be found in the study by Shore et al. and Casanova et al (60,119).  
Due to technical problems related to low laser power and hence reduced sensitivity 
of accurately picking up lower perfusion values with the laser Doppler device at the 
Dundee centre, the first half of SNP and ACh dose response curves are not reliable 
and have as a consequence not been included for analysis purposes. Therefore, 
while the standard approach to analysing this data would be a comparison of 
repeated measures dose response curves and the corresponding regression model, 
the following analysis will only focus on the mean peak response to ACh or SNP, 
calculated by taking the mean average of the last 3 readings in each individual 
subject’s dose response curve. This was done under the assumption of an accurately 
functioning laser Doppler device at higher perfusion values.  
 
 Statistical Analysis 
 
All statistical analyses were performed using the SPSS statistical software package 
version 25. Distribution of data was analysed for normality using the Shapiro-Wilk 
test. Differences in clinical characteristics between groups were investigated using 
Chi-square, Kruskal-Wallis or Mann-Whitney U-tests, as appropriate. Where the 
distribution of both assessed variables was normal, Pearson correlation was used. 
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Where the distribution of one or both variables was not normal, correlations were 
investigated using Spearman’s rho. A linear regression model was built using 
established cardiovascular risk factors from the Framingham and ASSIGN risk score 
calculators, β-amyloid, and significant determinants of β-amyloid identified in 
chapter 1. To analyse the association of plasma β-amyloid with clinically manifest 
CVD, the Chi-square test and Mantel-Haenszel linear by linear association test was 
used to explore the relationship between β-amyloid quartiles and CVD type at 
enrolment. To analyse whether β-amyloid was independently associated with follow 
up cardiovascular events, binary logistic regression was used. This analysis was only 





The following terms will be used throughout the analysis: the baseline SUMMIT 
cohort refers to the grouped cohort analysing both subjects with and without 
diabetes from both Dundee and Exeter centres of recruitment. The SUMMIT subjects 
with diabetes cohort will refer to subgroup analysis where only subjects with 
diabetes are included in the analysis (from both Dundee and Exeter). The same will 
apply for when the term SUMMIT subjects without diabetes cohort is used. The term 
Dundee baseline and Exeter baseline cohort will refer to all subjects from the 
corresponding centre of recruitment. Where the phrase ‘any CHD’ is used, this refers 
to all forms of coronary heart disease coded on the basis of previous myocardial 
infarction, unstable angina, stable angina, previous percutaneous coronary 
intervention (PCI) or previous coronary artery by-pass graft (CABG). Where the 
phrase ‘any cerebrovascular disease’ is used, this refers to all forms of 
cerebrovascular disease coded on the basis of stroke or transient ischaemic attack 
(TIA). Where the phrase ‘any lower extremity arterial disease’ (LEAD) is used, this 
refers to all forms of LEAD coded on the basis of intermittent claudication or 




 Patient Demographics  
 
The following table of baseline characteristics the SUMMIT cohort has been 
displayed in chapter 2 but for ease of reading the details have been summarised 
below.  Where the variable presented is a count, the number in brackets represents 
the equivalent %, where the number presented is a continuous variable, the number 
in brackets represents the standard deviation of that variable. Where significant 
differences exist between groups, the significance is illustrated using an asterisk (* = 
p<0.05, ** = p<0.01, *** = p<0.001). 
 
Table 3-2: Characteristics of the SUMMIT baseline cohort. 
 SUMMIT Baseline Cohort 




N 189 218 120 125 
Male sex n (%) *** 142 (75%) 120 (55%) 53 (44%) 94 (75%) 
Age years *** 67.7 (8.0) 63.9 (8.7) 63.1 (8.0) 68.5 (7.5) 
T2D Duration years *** 12.0 (8.3) 8.6 (6.1) NA NA 
BMI (kg/m2) *** 31.3 (5.1) 32.6 (5.9) 26.8 (4.3) 28.1 (4.1) 
Medication         
Statin use *** 168 (89%) 162 (74%) 20 (17%) 108 (86%) 
Antihypertensive 
use *** 
169 (89%) 138 (63%) 18 (15%) 93 (74%) 
Blood Pressure         
SBP  132.5 (18.1) 133.2 (16.3) 130.2 (16.4) 131.5 (18.3) 
DBP *** 73.1 (8.2) 77.3 (8.8) 77.1 (9.0) 74.8 (8.9) 
Metabolic parameters         
HbA1c mmol/mol 
*** 
61.9 (15.6) 59.0 (14.8) 40.1 (4.1) 39.0 (3.3) 
Total Cholesterol 
mmol/l *** 
3.8 (0.9) 4.1 (0.9) 5.4 (1.0) 4.2 (0.9) 
LDL Cholesterol 
mmol/l *** 
1.8 (0.7) 2.0 (0.8) 3.1 (0.9) 2.2 (0.8) 
HDL Cholesterol 
mmol/l *** 
1.2 (0.3) 1.3 (0.4) 1.6 (0.4) 1.4 (0.4) 
Triglycerides mmol/l 
*** 
1.8 (1.1) 1.8 (1.0) 1.4 (0.8) 1.3 (0.7) 
Renal Function         
Serum Creatinine 
umol/l *** 
92.6 (33.2) 78.0 (20.3) 74.3 (13.7) 84.0 (19.4) 
100 
 
ACR mg/mmol *** 6.9 (34.3) 2.7 (5.5) 0.9 (1.1) 1.9 (4.3) 
eGFR mL/min/1.73 m² 
*** 
 
77.2 (22.3) 86.1 (22.6) 86.9 (16.2) 82.0 (17.5) 
 
 Analysis of the SUMMIT Baseline Cohort 
 Correlation of Plasma β-amyloid with Markers of Cardiovascular Health 
 
In order to determine whether an association exists between plasma β-amyloid and 
markers of cardiovascular health, the first step was to use univariate correlations. 
Pearson or Spearman correlations were used as appropriate depending on the 
distribution of variables. The Bonferroni method was used to adjust for multiple 
comparisons, with the new threshold for statistical significance set at p<0.003. 
Simple scatter plots for significant correlations are displayed below. 
 
Table 3-3: Univariate correlations of plasma β-amyloid with markers of structural and 
functional change. 
Vascular Measurement Correlation Aβ40 Aβ42 
Mean Peak SNP Response Coefficient -0.249 -0.003 
  Sig. 3.01E-09 0.942 
  N 553 553 
Mean Peak ACh Response Coefficient -0.211 -0.40 
  Sig. 5.31E-07 0.350 
  N 555 555 
Reactive Hyperaemia Index 
(EndoPAT) 
Coefficient -0.044 -0.051 
  Sig. 0.275 0.207 
  N 605 605 
Reactive Hyperaemia Peak 
Perfusion 
Coefficient 0.085 -0.13 
  Sig.  0.063 0.004 
  N 480 481 
Pulse wave velocity Coefficient 0.282 0.114 
  Sig.  2.38E-11 0.008 
  N 540 541 
Mean common carotid IMT Right Coefficient 0.14 0.077 
  Sig.  4.60E-04 0.055 
  N 619 618 
Mean bulb IMT Right Coefficient 0.042 -0.033 
101 
 
Figure 3-9: Scatter plot of plasma β-amyloid 40 with the average of the 3 last readings on 
the SNP dose response curve in n=553 subjects, r=-0.249. 
Figure 3-10: Scatter plot of plasma β-amyloid 40 with the average of last 3 readings on 
the ACh dose response curve in n=555 subjects, r=-0.211. 
  Sig.  0.354 0.468 
  N 499 499 
Mean common carotid artery IMT 
Left 
Coefficient 0.107 -0.001 
  Sig. 0.007 0.971 
  N 621 621 
Mean bulb IMT Left Coefficient 0.109 0.024 
  Sig. 0.012 0.579 




































Figure 3-11: Scatter plot of plasma β-amyloid 40 with pulse wave velocity in 
n=540 subjects, r=0.282. 
Figure 3-12: Scatter plot of plasma β-amyloid 40 with right sided common 































Using univariate correlations, the analysis above looks at the association of β-
amyloid 40 and 42 with markers of vascular functional and structural health. After 
adjusting for multiple comparisons using the Bonferroni method, only β-amyloid 40 
showed significant correlations with vascular markers. A significant positive 
correlation was found when looking at β-amyloid 40 and pulse wave velocity as well 
as right-right sided CC intima media thickness. Significant negative correlations were 
found between β-amyloid 40 and the mean maximum response to SNP and Ach 
iontophoresis.  While β-amyloid 42 correlated with some vascular markers at the 
standard level of significance, p<0.05, none of these associations reached the newly 




 Regression Model: SUMMIT Baseline Cohort 
 
The next step was to determine whether the associations described above persisted 
after adjusting for conventional CVD risk factors. This linear regression model 
adjusted for cardiovascular risk factors present in the Framingham and ASSIGN risk 
score calculators: age, gender, diabetes status, SBP, total cholesterol and HDL 
cholesterol. Additionally, in order to determine whether the effect of β-amyloid was 
independent of any factors identified by the analysis in chapter 2 such as renal 
function or insulin use, this model also adjusted for independent predictors of 
plasma β-amyloid 40 and 42. For β-amyloid 40 in the SUMMIT baseline cohort these 
were eGFR and diuretic use, and for β-amyloid 42 these were eGFR, diuretic use and 
LDL cholesterol. Beta refers to the standardised regression coefficient to allow for 
easy comparisons between models. Each row with corresponding β-amyloid column 
in the table below refer to an individual regression model. 
 
 
Table 3-4: Summary of individual regression models with independent variables age, 
gender, diabetes status, SBP, total cholesterol, HDL cholesterol, β-amyloid 40 or 42 and 
either eGFR + diuretic use or eGFR + diuretic use + LDL cholesterol. 
Dependent Variable Aβ40 (pg/ml) Aβ42 (pg/ml) 
Beta p-value Beta p-value 
Reactive Hyperaemia Peak Perfusion (PU) 0.116 0.019 -0.107 0.035 
Reactive Hyperaemia Index (EndoPAT 
units) 
0.003 0.952 -0.021 0.618 
Pulse Wave Velocity (m/s) 0.17 5.00E-06 0.023 0.559 
Common Carotid IMT Right (mm) 0.033 0.413 0.005 0.906 
Mean Bulb IMT Right (mm) 0.027 0.557 -0.01 0.828 
Common Carotid IMT Left (mm) -0.007 0.868 -0.047 0.271 
Mean Bulb IMT Left (mm) 0.083 0.076 0.076 0.11 
Peak SNP Response (PU) -0.175 9.10E-05 0.033 0.473 
Peak ACh Response (PU) -0.154 0.001 0.011 0.813 
 
After adjusting for conventional risk factors described above as well as clinical 
determinants of plasma β-amyloid 40 and 42, β-amyloid was 40 was found to be 
significantly associated with reactive hyperaemia, pulse wave velocity, peak SNP 
response and peak ACh response. β-amyloid 42 was only significantly associated 
with a reduced peak reactive hyperaemia perfusion response.  
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 Association of Aβ quartiles with clinically manifest CVD at enrolment into 
study 
 
Having investigated the association between plasma β-amyloid and biomarkers of 
cardiovascular health, the next step was to determine how plasma β-amyloid varies 
with different forms of clinically manifest CVD. The following cross tabulations refer 
to the association between SUMMIT baseline cohort β-amyloid quartiles, coronary 
heart disease, lower extremity arterial disease and cerebrovascular disease status at 
enrolment into the study. β-amyloid 40 quartiles are presented first. The Mantel 
Haenszel test for trend is a modified Chi-square test whereby significance suggests 
that association between the predictor and outcome variable is significantly 
different in the different levels of the conditional variable.  To adjust for multiple 




Table 3-5: Cross tabulation summarising number of subjects with CHD in each β-amyloid 
40 quartile at enrolment into study. 
 SUMMIT Baseline Cohort 
  
Any CHD  Total 




0.6-207.9 98 64 162 
208-251.7 109 51 160 
251.8 – 314.4 104 58 162 
314.5-650.2 97 62 159 
Total 408 235 643 
Mantel-Haenszel linear by linear association: 𝑥2(1)=0.017, p=0.896 
 
 
Table 3-6: Cross tabulation summarising number of subjects with LEAD in each β-amyloid 
40 quartile at enrolment into study. 
SUMMIT Baseline Cohort 
  
  
Any LEAD Total 




0.6-207.9 150 12 162 
208-251.7 144 16 160 
251.8 – 314.4 143 19 162 
314.5-650.2 118 41 159 
Total 555 88 643 





Table 3-7: Cross tabulation summarising number of subjects with cerebrovascular disease 
in each β-amyloid 40 quartile at enrolment into study. 
SUMMIT Baseline Cohort Cerebrovascular 
Disease 
Total 




0.6-207.9 150 12 162 
208-251.7 143 17 160 
251.8 – 314.4 149 13 162 
314.5-650.2 131 28 159 
Total 573 70 643 
Mantel-Haenszel linear by linear association: 𝑥2(1)=6.42, p=0.011 
 
Table 3-8: Cross tabulation summarising number of subjects with CHD in each β-amyloid 
42 quartile at enrolment into study. 
 SUMMIT Baseline Cohort Any CHD Total 




0.06-9.64 97 64 161 
9.65-12.1 111 50 161 
12.2-14.78 112 49 161 
14.79-37.43 88 72 160 
Total 408 235 643 
Mantel-Haenszel linear by linear association: 𝑥2(1)=0.78, p=0.378 
 
 
Table 3-9: Cross tabulation summarising number of subjects with LEAD in each β-amyloid 
42 quartile at enrolment into study. 
SUMMIT baseline cohort  Any LEAD Total 




0.06-9.64 138 23 161 
9.65-12.1 140 21 161 
12.2-14.78 142 19 161 
14.79-37.43 137 23 160 
Total 557 86 643 












Table 3-10: Cross tabulation summarising number of subjects with cerebrovascular disease 
in each β-amyloid 42 quartile at enrolment into study. 







0.06-9.64 146 15 161 
9.65-12.1 148 13 161 
12.2-14.78 144 17 161 
14.79-37.43 135 25 160 
Total 573 70 643 
Mantel-Haenszel linear by linear association: 𝑥2(1)=3.78, p=0.052 
 
 
The above analysis used a variation of the Chi-Square test, the Mantel-Haenszel test 
for trend to determine whether a significant association exists between β-amyloid 
quartiles and different types of clinically manifest CVD at enrolment into the study. 
At the new threshold for significance (p<0.008) increasing β-amyloid 40 quartiles 



























 Analysis of Plasma β-amyloid Levels and Cardiovascular Outcomes 
 
Having performed a cross-sectional type analysis looking at clinically manifest CVD at 
enrolment into the study in relation to plasma beta amyloid levels, the next step was 
to analyse any associations with clinically manifest CVD over a prospective follow up 
period. Ideally, to determine the association between β-amyloid and cardiovascular 
outcomes, a more robust analysis would have been to use Cox regression taking into 
account time to event.  However, due to the lack of information about time of event 
within the available database, a logistic regression model was used instead of a 
survival analysis model. The following table summarises the results of a binary 
logistic regression model looking at patient outcomes accumulated over a period of 
4-6 years of follow up. This model adjusted for risk factors used in Framingham and 
ASSIGN risk score calculators. These include age, gender, diabetes status, total 




Table 3-11: Summary of individual binary logistic regression models with independent 
variables age, gender, diabetes status, total cholesterol, HDL cholesterol, systolic BP and β-
amyloid 40 or 42. 
Outcome – Dependent Variable Aβ40 (pg/ml) Aβ42 (pg/ml) 
Exp(B) p-value Exp(B) p-value 
Death from any cause (n=18) 1.00 0.879 0.966 0.515 
Acute MI (n=14) 0.997 0.235 0.943 0.321 
Unstable Angina (n=20) 0.999 0.630 0.962 0.445 
Stroke (n=6) 1.001 0.855 1.094 0.258 
TIA (n=12) 0.996 0.280 0.983 0.777 
Intermittent Claudication  (n=17) 1.002 0.574 0.981 0.748 
Composite Cardiovascular Outcomes 
(n=70) 
1.000 0.792 0.957 0.625 
 
Using binary logistic regression with cardiovascular individual or composite 
cardiovascular outcomes as dependent variables and established CVD risk factors as 
well as β-amyloid 40 and 42 as independent variables, neither β-amyloid 40 nor β-
amyloid 42 were found to be significantly independently associated with any 








 Analysis of SUMMIT Subjects Without T2DM  
 
In order to determine whether some of the associations found in the SUMMIT 
baseline cohort were also present in subjects with and without diabetes individually, 
the initial analysis was repeated in subjects without diabetes and subjects with 
diabetes individually. Although diabetes status was not a significant independent 
predictor of β-amyloid levels in regression models in the previous chapter, based on 
findings from our previous animal study as well as studies from other research 
groups, diabetes status was deemed to be of clinical importance. 
 
 SUMMIT Subjects Without Diabetes: Correlations of Plasma β-amyloid 
with Biomarkers of Cardiovascular Health 
 
The first step was to analyse plasma β-amyloid in relation to biomarkers of 
cardiovascular health in groups of subjects with and without diabetes. The following 
analysis will first display results for SUMMIT subjects without diabetes, followed by 
results for those with diabetes.  Depending on variable distribution, either Pearson 
or Spearman correlation was used to determine whether a significant univariate 
correlation exists between plasma β-amyloid 40 or 42 and biomarkers of 
cardiovascular health. Scatterplots for significant associations are displayed below. 
The Bonferroni method was used to correct for multiple comparisons by dividing the 
standard p value 0.05 by the number of comparisons made, with the new threshold 









Table 3-12: Univariate correlations of plasma β-amyloid with markers of vascular 
structural or functional change in SUMMIT subjects without diabetes. 




Reactive Hyperaemia Index (EndoPAT) Correlation Coefficient 0.084 0.001 
  Sig. 0.201 0.992 
  N 235 235 
Reactive Hyperaemia Peak Perfusion 
(PU) 
Correlation Coefficient 0.039 -0.091 
  Sig.  0.584 0.206 
  N 195 196 
Pulse wave velocity (m/s) Correlation Coefficient 0.268 0.037 
  Sig. 4.60E-05 0.585 
  N 225 226 
Mean CC IMT Right (mm) Correlation Coefficient 0.216 0.106 
  Sig. 0.001 0.104 
  N 238 238 
Mean CC Bulb IMT Right (mm) Correlation Coefficient 0.046 -0.119 
  Sig. 0.523 0.093 
  N 199 199 
Mean CC IMT Left (mm) Correlation Coefficient 0.109 -0.003 
  Sig. 0.093 0.958 
  N 237 237 
Mean CC Bulb IMT Left (mm) Correlation Coefficient 0.107 -0.046 
  Sig. 0.123 0.51 
  N 208 208 
Mean Peak ACh Response (PU) Correlation Coefficient -0.054 0.079 
  Sig. 0.434 0.246 
  N 214 215 
Mean Peak SNP Response (PU) Correlation Coefficient -0.099 0.15 
  Sig.  0.153 0.029 





































A univariate analysis of plasma β-amyloid with markers of vascular structural and 
functional health in subjects without T2DM revealed 2 significant positive 
correlations. β-amyloid 40 was found to correlate positively with pulse wave velocity 
as well as mean right-sided CC IMT. No significant correlations were found when 





Figure 3-13: Scatter plot of β-amyloid 40 with pulse wave velocity in 
SUMMIT subjects without diabetes, n=225, r=0.268. 
Figure 3-14: Scatter plot of β-amyloid 40 with right-sided mean common 
carotid IMT in SUMMIT subjects without diabetes, n=238, r=0.216. 
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 Regression Model: SUMMIT Subjects without Diabetes 
 
The next step was to determine whether any significant associations discovered in 
univariate correlation of plasma β-amyloid with biomarkers of vascular health 
persisted after adjusting for common CVD risk factors. These models included 
recognised CVD risk factors included in the Framingham and ASSIGN risk score 
calculators and adjusted for age, gender, systolic blood pressure, total cholesterol 
and HDL cholesterol. Where the effect of β-amyloid 40 was investigated, the model 
also adjusted for eGFR and height (age already included), as these were significant 
predictors of β-amyloid in Chapter 2. Where the model investigated the effect of β-
amyloid 42, eGFR was also included in the model. Each row with corresponding β-
amyloid column in the table below represents an individual regression model.  
 
Table 3-3-13: Summary of individual linear regression models with independent variables 
age, gender, SBP, total cholesterol, HDL cholesterol as well as β-amyloid 40 or 42 and 
eGFR, Height or eGFR respectively. 
Vascular Measurement – Dependent 
Variable 
Aβ40 (pg/ml) Aβ42 (pg/ml) 
Beta p-value Beta p-value 
Reactive Hyperaemia Peak Perfusion (PU) 0.047 0.54 -0.14 0.066 
Reactive Hyperaemia Index (EndoPAT 
units) 
0.068 0.336 -0.052 0.457 
Pulse Wave Velocity (m/s) 0.17 0.003 0.011 0.84 
Common Carotid IMT Right (mm) 0.062 0.324 0.079 0.195 
Mean Bulb IMT Right (mm) -0.052 0.464 -0.113 0.112 
Common Carotid IMT Left (mm) -0.021 0.75 -0.022 0.733 
Mean Bulb IMT Left (mm) 0.083 0.249 -0.019 0.766 
Mean SNP Response (PU) -0.031 0.675 0.123 0.016 
Mean ACh Response (PU) -0.005 0.945 0.173 0.091 
 
The above analysis shows that after adjusting for common CVD risk factors as well as 
clinical determinants of β-amyloid identified in chapter 2, higher β-amyloid 40 levels 
were significantly independently associated with pulse wave velocity. Interestingly, 
the univariate correlation between β-amyloid 42 and SNP was not significant at the 
Bonferroni adjusted p-value threshold, however, in the above linear regression 
model β-amyloid 42 was found to be significantly and independently associated with 




 Analysis of Plasma β-amyloid in relation to Clinically Manifest 
Cardiovascular Disease – SUMMIT Subjects Without Diabetes 
 
Having investigated the relationship between plasma β-amyloid and biomarkers of 
cardiovascular health or disease risk, the next step was to determine whether any 
association exists between plasma β-amyloid levels and clinically manifest CVD. The 
following cross tabulations summarise the associations between plasma β-amyloid 
40 and 42 quartiles and different forms of CVD at enrolment into study. The Mantel 
Haenszel test for trend is a modified Chi-square test whereby significance suggests 
that association between the predictor and outcome variable is significantly 
different in the different levels of the conditional variable. Using the Bonferroni 
method, the new threshold for significance was again set at p<0.008.  
 
Table 3-14: Cross tabulation summarising number of cases of CHD in each β-amyloid 40 
quartile at enrolment into the study in SUMMIT subjects without diabetes. 
 SUMMIT Subjects 
Without T2DM 





0.60-205.34 36 25 61 
205.35-243.4 41 20 61 
243.5-287.3 33 28 61 
287.4-650.2 42 19 61 
Total 152 92 244 




Table 3-15: Cross tabulation summarising number of cases of LEAD in each β-amyloid 40 
quartile at enrolment into the study in SUMMIT subjects without diabetes 
SUMMIT Subjects 
Without T2DM  





0.60-205.34 59 2 61 
205.35-243.4 56 5 61 
243.5-287.3 53 8 61 
287.4-650.2 53 8 61 
Total 221 23 244 








Table 3-16: Cross tabulation summarising number of cases of cerebrovascular disease in 
each β-amyloid 40 quartile at enrolment into the study in SUMMIT subjects without 
diabetes. 









0.60-205.34 57 4 61 
205.35-243.4 55 6 61 
243.5-287.3 53 8 61 
287.4-650.2 48 13 61 
Total 213 31 244 
Mantel-Haenszel linear by linear association: 𝑥2(1)=6.19, p=0.013 
 
Table 3-17: Cross tabulation summarising number of cases of CHD in each β-amyloid 42 
quartile at enrolment into the study in subjects without diabetes. 
SUMMIT Subjects 
Without Diabetes 





0.21-9.15 36 26 62 
9.16-11.57 42 18 60 
11.58-14.3 39 22 61 
14.4-27.98 35 26 61 
Total 152 92 244 
Mantel-Haenszel linear by linear association: 𝑥2(1)=0.078, p=0.780 
 
 
Table 3-18: Cross tabulation summarising number of cases of LEAD in each β-amyloid 42 
quartile at enrolment into the study, in SUMMIT subjects without diabetes. 
SUMMIT Subjects 
Without T2DM 





0.21-9.15 54 8 62 
9.16-11.57 58 2 60 
11.58-14.3 54 7 61 
14.4-27.98 56 5 61 
Total 222 22 244 









Table 3-19: Cross tabulation summarising number of cases of cerebrovascular disease in 












Mantel-Haenszel linear by linear association: 𝑥2(1)=3.08, p=0.079 
 
 
Using the Mantel-Haenszel test for trend, no significant associations were found 






































0.21-9.15 55 7 62 
9.16-11.57 58 2 60 
11.58-14.3 51 10 61 
14.4-27.98 50 11 61 
Total 214 30 244 
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 Analysis of SUMMIT Subjects With T2DM 
 Correlation of Plasma β-amyloid with biomarkers of cardiovascular health 
in the SUMMIT diabetic cohort 
 
The same analysis performed above was then repeated for SUMMIT subjects with 
T2DM. In order to determine whether plasma β-amyloid was associated with any 
biomarkers of cardiovascular health/disease risk, univariate correlations were 
examined. Depending on the distribution of variables, either Spearman or Pearson 
correlations were used. As before, the Bonferroni method was used to correct for 
multiple comparisons, with a new threshold for significance set at p<0.003. 
Scatterplots for significant associations are displayed below. 
 
Table 3-20: Summary of univariate correlations of β-amyloid 40 and 42 with markers of 
structural or functional vascular changes in SUMMIT subjects with diabetes 




Reactive Hyperaemia Index (EndoPAT 
units) 
Correlation Coefficient -0.068 -0.052 
  Sig.  0.193 0.321 
  N 370 370 
Reactive Hyperaemia Peak Perfusion 
(PU) 
Correlation Coefficient 0.128 -0.159 
  Sig. 0.031 0.007 
  N 285 285 
Pulse wave velocity (m/s) Correlation Coefficient 0.289 0.145 
  Sig. 1.74E-07 0.01 
  N 315 315 
Mean Common Carotid  IMT Right 
(mm) 
Correlation Coefficient 0.088 0.043 
  Sig. 0.085 0.403 
  N 381 380 
Mean CC Bulb IMT Right (mm) Correlation Coefficient 0.021 -0.006 
  Sig. 0.72 0.915 
  N 300 300 
Mean Common Carotid IMT Left 
(mm) 
Correlation Coefficient 0.092 -0.02 
  Sig. 0.071 0.695 
  N 384 384 
Mean CC Bulb IMT Left (mm) Correlation Coefficient 0.105 0.056 
  Sig. 0.063 0.321 
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  N 315 316 
Mean Peak ACh Response (PU) Correlation Coefficient -0.282 -0.09 
  Sig. 1.17E-07 0.096 
  N 341 340 
Mean Peak SNP Response (PU) Correlation Coefficient -0.311 -0.054 
  Sig. 4.46E-09 0.321 









































Figure 3-15: Scatter plot of plasma β-amyloid 40 with pulse wave velocity in 
SUMMIT subjects with diabetes, n=315, r=0.289. 
Figure 3-16: Scatter plot of plasma β-amyloid 40 with peak ACh response in 



















The above univariate analysis in subjects with T2DM shows that significant negative 
correlations exist between β-amyloid 40 and peak response to ACh as well as SNP 
iontophoresis. Additionally, as seen in previous univariate analyses, a significant 

























Figure 3-17: Scatter plot of plasma β-amyloid 40 with peak SNP response in 
SUMMIT subjects with diabetes, n=341, r=-0.311. 
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 Regression: SUMMIT Subjects With T2DM 
 
To determine whether the associations of plasma β-amyloid with biomarkers of 
cardiovascular disease persist even after adjusting for common CVD risk factors, a 
linear regression model was used. These models adjust for age, gender, systolic 
blood pressure, total cholesterol, HDL cholesterol and smoking status. Where β-
amyloid 40 was included in the model, additional factors adjusted for included eGFR, 
insulin use and diuretic use. Where β-amyloid 42 was included in the model, factors 
adjusted for also included eGFR and insulin use. Each row with corresponding β-
amyloid column in the table below represents an individual regression model. 
 
Table 3-21: Summary of linear regression models with independent variables age, gender, 
systolic blood pressure, total cholesterol, HDL cholesterol an either β-amyloid 40 or 42, 
with eGFR, insulin use and diuretic use or eGFR and insulin use respectively. 
Vascular Measurement – Dependent 
Variable 
Aβ40 (pg/ml) Aβ42 (pg/ml) 
Beta p-value Beta p-value 
Reactive Hyperaemia Peak Perfusion (PU) 0.179 0.008 -0.105 0.113 
Reactive Hyperaemia Index (EndoPAT 
units) 
-0.027 0.636 -0.007 0.903 
Pulse Wave Velocity (m/s) 0.153 0.003 0.03 0.559 
Common Carotid IMT Right (mm) 0.017 0.76 -0.05 0.355 
Mean Bulb IMT Right (mm) 0.055 0.382 0.032 0.604 
Common Carotid IMT Left (mm) -0.001 0.992 -0.059 0.102 
Mean Bulb IMT Left (mm) 0.082 0.19 0.101 0.1 
Mean Peak SNP Response (PU) -0.229 1.19E-04 -0.034 0.568 
Mean Peak ACh Response (PU) -0.263 1.10E-05 -0.04 0.499 
 
 
In subjects with T2DM, a linear regression analysis showed that β-amyloid 40 was 
significantly and independently associated with peak reactive hyperaemia response, 
pulse wave velocity, peak response to SNP as well as ACh iontophoresis, even after 
adjusting for conventional CVD risk factors and clinical determinants of β-amyloid. β-
amyloid 42 was not found to be independently associated with any of the markers of 







 Analysis of Plasma β-amyloid in relation to Clinically Manifest 
Cardiovascular Disease – SUMMIT Subjects With T2DM 
 
The following analysis was used to investigate the association between plasma β-
amyloid and clinically manifest CVD. Due to small numbers of accumulated 
outcomes, no follow up outcome analysis was performed. The Mantel Haenszel test 
for trend is a modified Chi-square test whereby significance suggests that association 
between the predictor and outcome variable is significantly different in the different 
levels of the conditional variable. As previous, the Bonferroni method was used to 
set the new threshold for significance at p<0.008.  
 
Table 3-22: Cross tabulation summarising number of cases of CHD in each β-amyloid 40 
quartile, in SUMMIT subjects with T2DM at enrolment into study. 
 SUMMIT Subjects With 
T2DM 





0.80-211.3 62 38 100 
211.4-258.7 73 27 100 
258.8-325.9 65 35 100 
326-633.4 56 43 99 
Total 256 143 399 
Mantel-Haenszel linear by linear association: 𝑥2(1)=1.263, p=0.261 
 
 
Table 3-23: Cross tabulation summarising number of cases of LEAD in each β-amyloid 40 
quartile at enrolment into the study in SUMMIT subjects with T2DM. 
 SUMMIT Subjects With 
T2DM 





0.80-211.3 91 9 100 
211.4-258.7 89 11 100 
258.8-325.9 87 13 100 
326-633.4 67 32 99 
Total 334 65 399 










Table 3-24: Cross tabulation summarising number of cases of cerebrovascular disease in 
each β-amyloid 40 quartile at enrolment into the study, in SUMMIT subjects with T2DM. 









0.80-211.3 92 8 100 
211.4-258.7 90 10 100 
258.8-325.9 94 6 100 
326-633.4 84 15 99 
Total 360 39 399 




Table 3-25: Cross tabulation summarising number of cases of CHD in each β-amyloid 42 
quartile at enrolment into study in SUMMIT subjects with T2DM. 
 SUMMIT Subjects With 
T2DM 





0.06-9.8 61 39 100 
9.9-12.5 70 30 100 
12.6-14.9 72 28 100 
15-37.43 53 46 99 
Total 256 143 399 
Mantel-Haenszel linear by linear association: 𝑥2(1)=0.878, p=0.349 
 
 
Table 3-26: Cross tabulation summarising number of cases of LEAD in each β-amyloid 42 
quartile at enrolment into study, in SUMMIT subjects with T2DM. 
 SUMMIT Subjects With 
T2DM 





0.06-9.8 85 15 100 
9.9-12.5 82 18 100 
12.6-14.9 88 12 100 
15-37.43 80 19 99 
Total 335 64 399 










Table 3-27: Cross tabulation summarising number of cases of cerebrovascular disease in 
each β-amyloid 42 quartile at enrolment into study, in SUMMIT subjects with T2DM. 









0.06-9.8 90 10 100 
9.9-12.5 93 7 100 
12.6-14.9 91 9 100 
15-37.43 85 14 99 
Total 359 40 399 
Mantel-Haenszel linear by linear association: 𝑥2(1)=1.136, p=0.282 
 
 
In the above analysis, a modified version of the Chi-Square test was used to 
investigate the relationship between β-amyloid quartiles and different types of 
clinically manifest CVD at enrolment into the study. A significant association was 
seen between increasing β-amyloid 40 quartiles and number of LEAD cases, where 




 Summary of key findings from the SUMMIT cohort: 
 SUMMIT Baseline Cohort 
 
Linear regression analysis showed that higher β-amyloid 40 levels were significantly 
and independently associated with increased peak reactive hyperaemia response to 
temporary blood flow occlusion and increased pulse wave velocity. Increasing β-
amyloid levels 40 were also significantly and independently associated with reduced 
peak perfusion response to SNP and ACh iontophoresis.  β-amyloid 42 was 
significantly and independently associated with reduced reactive hyperaemia 
response following temporary blood flow occlusion.  
When looking at clinically manifest CVD at time of enrolment into the study, 
increasing β-amyloid 40 levels appear to be associated with increased numbers of 
LEAD cases. No associations are seen with β-amyloid 42.  No significant association 





 SUMMIT Non-T2DM Cohort 
 
Linear regression analysis revealed that higher β-amyloid 40 levels were significantly 
and independently associated with increased pulse wave velocity and higher β-
amyloid 42 levels were significantly associated with increased peak response to SNP 
iontophoresis.  
 SUMMIT T2DM Cohort 
 
Linear regression analysis revealed significant associations between β-amyloid 40 
and increased reactive hyperaemia response to temporary blood flow occlusion, 
pulse wave velocity and reduced peak response to SNP and ACh iontophoresis. 
Additionally, increasing β-amyloid 40 levels were also associated with increasing 
numbers of LEAD cases at enrolment into study. No significant associations were 


























 Sub-Group Analysis By Centre of Recruitment 
 
Having completed the analysis of the baseline SUMMIT cohort as well as subgroup 
analysis looking at subjects with and without diabetes, the next step was to perform 
a subgroup analysis looking at individual centres of recruitment separately. This was 
done, as subjects recruited in different centres differed significantly in terms of 
baseline characteristics as well as β-amyloid levels. The following table summarises 
baseline patient data for each centre of recruitment. Where a significant difference 
was found between centres of recruitment, the level of statistical significance is 
illustrated. Mean comparisons were performed using either the Mann-Whitney or 
Independent T-tests depending on distribution of variables. * = p<0.05, ** = p<0.01, 
*** = p<0.001. 
 
Table 3-28: Summary of baseline patient characteristics in each centre of recruitment, 
significant differences are illustrated with *. 




N 376 276 
Male sex n (%) 220 (59%) 189 (68%) 
Age (SD) 65.2 (8.4) 66.9 (8.9)** 
BMI (kg/m2) 30.7 (5.5) 29 (5.1)*** 
Medication     
Statin use 273 (73%) 185 (67%) 
Antihypertensive use 255 (68%) 163 (59%)* 
Blood Pressure     
SBP 133.6 (17.2) 130 (15.6)* 
DBP 76.8 (8.7) 73.6 (8.5)*** 
Metabolic parameters     
HbA1c mmol/mol 51.7 (15.0) 51.5 (14.8) 
Total Cholesterol 
mmol/l 
4.1 (1.0) 4.4 (1.1) *** 
LDL Cholesterol mmol/l 2.1 (0.9) 2.4 (1.0) *** 
HDL Cholesterol mmol/l 1.3 (0.4) 1.4 (0.4) *** 
Triglycerides mmol/l 1.7 (0.8) 1.4 (0.7) *** 
Renal Function     
Serum Creatinine 
umol/l 
81.2 (26.1) 84.9 (13.5)*** 





 Comparison of the effect of cardiovascular disease and diabetes status on 
β-amyloid levels based on centre of recruitment 
 
To determine whether plasma β-amyloid levels differ in subjects with or without 
diabetes and with or without CVD across the different centres, the Mann-Whitney or 
Independent T test was used to make both within centre and between centre 







































Figure 3-19: Bar graphs comparing β-amyloid 40 levels in different patient groups 
between centres of recruitment. 
Figure 3-18: Bar graphs comparing β-amyloid 42 levels in different patient groups 
between centres of recruitment. 
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The above graphs show that significant differences in β-amyloid 40 levels exist 
between the Dundee and Exeter centres when looking at subjects with T2DM and 
with or without CVD. Additionally, a significant difference is also seen in β-amyloid 
42 levels between Dundee and Exeter centres when looking at subjects without 
T2DM but with CVD.  Together with significant differences in a number of baseline 
characteristics, this suggested that it would be of value to repeat some of the 
analyses done for the SUMMIT database separately for centres of recruitment.  
  
 Analysis of the Dundee Baseline Cohort 
 Dundee Baseline Cohort: Correlations of Plasma β-amyloid With Vascular 
Biomarkers 
 
Results from the Dundee cohort are presented first. Univariate correlations were 
used to determine the association between plasma β-amyloid and markers of 
vascular structural or functional changes. Depending on the distribution of variables, 
either Spearman or Pearson correlations were used. As previously, the Bonferroni 
method was used to correct for multiple comparisons, by dividing 0.05 by the 
number of comparisons made (Bonferroni adjusted level of significance p<0.003). 
Scatterplots for significant univariate correlations are displayed below.  
 
Table 3-29: Summary of univariate correlations between plasma β-amyloid and markers of 
vascular structural or functional change in the Dundee baseline cohort. 
Vascular Measurement Correlation  Aβ40 Aβ42 
Reactive Hyperaemia Index 
(EndoPAT)  
Correlation Coefficient -0.069 -0.178 
  Sig. 0.198 0.001 
  N 347 347 
Reactive Hyperaemia Peak 
Perfusion (PU) 
Correlation Coefficient -0.121 -0.282 
  Sig. 0.066 1.2E-5 
  N 232 233 
Pulse wave velocity (m/s) Correlation Coefficient 0.333 0.214 
  Sig. 7.67E-09 2.53E-4 
  N 287 288 
Mean common carotid artery IMT 
Right (mm) 
Correlation Coefficient 0.192 0.129 
  Sig. 3.24 E-4 0.017 
  N 347 346 
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Figure 3-21: Scatter plot of β-amyloid 40 with right sided CC IMT in the 
Dundee baseline cohort, n=347, r=0.192 
Mean bulb IMT Right (mm) Correlation Coefficient 0.2 0.017 
  Sig. 0.001 0.784 
  N 250 250 
Mean common carotid artery IMT 
Left (mm) 
Correlation Coefficient 0.123 0.008 
  Sig.  0.021 0.875 
  N 352 352 
Mean bulb IMT Left (mm) Correlation Coefficient 0.127 0.031 
  Sig. 0.032 0.6 
  N 283 284 
Mean Peak SNP Response (mm) Correlation Coefficient -0.185 -0.088 
  Sig.  0.001 0.133 
  N 294 294 
Mean Peak ACh Response Correlation Coefficient -0.143 -0.105 
  Sig. (2-tailed) 0.014 0.07 


























Figure 3-20: Scatter plot of β-amyloid 40 with pulse wave velocity in the Dundee 

















































Figure 3-24: Scatter plot of β-amyloid 42 with reactive hyperaemia index as 
measured by EndoPAT in the Dundee baseline cohort, n=347, r=-0.178. 
Figure 3-22: Scatter plot of β-amyloid 40 with right-sided mean common 
carotid bulb IMT in the Dundee baseline cohort, n=250, r=0.200. 
Figure 3-23: Scatter plot of β-amyloid 40 with peak response to SNP in the 
Dundee baseline cohort, n=294, r=-0.185 
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Figure 3-25: Scatter plot of β-amyloid 42 with reactive hyperaemia in the Dundee 
baseline cohort, n=233, r=-0.282 
Figure 3-26: Scatter plot of β-amyloid 42 with pulse wave velocity in the Dundee 
































The above univariate correlations look at the Dundee subgroup separately. After 
Bonferroni adjustment to the new accepted threshold of significance at 0.003, 
significant positive correlations were found between β-amyloid 40 with pulse wave 
velocity, mean right-sided CC IMT and mean right sided bulb IMT, while a significant 
negative correlation was seen with the mean peak SNP response.  
For β-amyloid 42, a significant negative correlation is seen with peak reactive 
hyperaemia response to temporary occlusion as well as RHI as measured by 
EndoPAT. Significant positive correlations can be seen between β-amyloid 42 with 
pulse wave velocity and right-sided CC IMT.  
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 Linear Regression: Dundee Baseline cohort 
 
As performed previously, a regression model was then built to determine whether 
any associations seen during univariate analysis persisted after adjusting for 
common CVD risk factors. This model adjusted for age, gender, diabetes status, total 
cholesterol, HDL cholesterol as well as factors identified as significant predictors of 
plasma β-amyloid in chapter 1. For β-amyloid 40 in the baseline cohort these were 
eGFR and diuretic use, and for β-amyloid 42 these were eGFR, diuretic use and LDL 
cholesterol. Beta refers to the standardised correlation coefficient. Each row and 
corresponding β-amyloid column represent a separate linear regression model with 
the dependent variable highlighted.  
 
Table 3-30: Linear regression models with independent variables age, gender, diabetes 
status, total cholesterol, HDL cholesterol and either β-amyloid 40 or 42 with eGFR + 
diuretic use or eGFR + diuretic use + LDL cholesterol respectively.  
Vascular Measurement – Dependent 
Variable 
Aβ40 (pg/ml) Aβ42 (pg/ml) 
Beta p-value Beta p-value 
Reactive Hyperaemia Peak Perfusion (PU) -0.033 0.693 -0.215 0.009 
Reactive Hyperaemia Index (EndoPAT 
units) 
0.015 0.801 -0.074 0.223 
Pulse Wave Velocity (m/s) 0.193 0.001 0.116 0.048 
Common Carotid IMT Right (mm) 0.082 0.185 -0.001 0.988 
Mean Bulb IMT Right (mm) 0.119 0.096 -0.03 0.678 
Common Carotid IMT Left (mm) 0.051 0.424 -0.058 0.358 
Mean Bulb IMT Left (mm) 0.102 0.15 0.038 0.594 
Mean SNP Response (PU) -0.016 0.815 0.026 0.707 
Mean ACh Response (PU) -0.041 0.553 0.015 0.831 
 
 
The above regression table summarises individual regression models. β-amyloid 40 
was only found to be a significantly independently associated with pulse wave 
velocity, while β-amyloid 42 was seen to be significantly and independently 






 Analysis of Dundee Subjects Without T2DM 
 Univariate Correlations in Dundee Subjects without T2DM 
 
The same analysis was then repeated in Dundee subjects without T2DM. The first 
step was to analyse the association between plasma β-amyloid and biomarkers of 
cardiovascular health. Depending on the distribution of variables, either the Mann-
Whitney or independent T-tests were used. The Bonferroni method was used to 
correct for multiple comparisons, by dividing the p value 0.05 by number of 
comparisons made (adjusted p-value , p=0.003). Scatter plots for significant 
correlations are displayed below.  
 
Table 3-31: Summary of univariate correlations of plasma β-amyloid with markers of 
vascular structural or functional changes in Dundee subjects without T2DM. 




Reactive Hyperaemia Index (EndoPAT 
units) 
Correlation Coefficient 0.078 0.007 
  Sig. 0.383 0.94 
  N 127 127 
Reactive Hyperaemia Peak Perfusion 
(PU) 
Correlation Coefficient -0.013 -0.09 
  Sig.  0.901 0.397 
  N 90 91 
Pulse wave velocity (m/s) Correlation Coefficient 0.256 0.176 
  Sig.  0.006 0.058 
  N 116 117 
Mean Common Carotid IMT Right (mm) Correlation Coefficient 0.276 0.114 
  Sig. 0.002 0.2 
  N 127 127 
Mean Bulb IMT Right (mm) Correlation Coefficient 0.249 -0.096 
  Sig. 0.014 0.349 
  N 97 97 
Mean Common Carotid IMT Left (mm) Correlation Coefficient 0.15 -0.02 
  Sig. 0.092 0.823 
  N 127 127 
Mean Bulb IMT Left (mm) Correlation Coefficient 0.304 0.06 
  Sig. 0.002 0.549 
  N 103 103 
Mean Peak SNP Response (PU) Correlation Coefficient -0.167 -0.091 
  Sig. 0.085 0.349 
  N 107 108 
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Mean Peak ACh Response (PU) Correlation Coefficient -0.082 -0.031 
  Sig. 0.397 0.746 








Univariate correlations were then repeated after further subdividing Dundee 
subjects based on T2DM status. After the Bonferroni correction, significant 
univariate correlations were seen with β-amyloid 40 and mean right-sided CC and 
bulb IMT. No significant univariate correlations were seen with β-amyloid 42. 
 
Figure 3-27: Scatter plot of β-amyloid 40 with right-sided mean common 
carotid IMT in Dundee subjects without T2DM, n=127, r=0.276. 
Figure 3-28: Scatter plot of β-amyloid 40 with left sided mean common 
carotid bulb IMT in Dundee subjects without T2DM, n=103, r=0.304. 
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 Regression Models: Dundee Subjects Without T2DM 
 
Linear regression was then use to determine whether any associations with β-
amyloid persisted after adjusting for common CVD risk factors. These linear 
regression models adjusted for established risk factors used in the Framingham and 
ASSIGN CVD risk scores. These were Age, Gender, SBP, HDL cholesterol and Total 
cholesterol. This model also adjusted for significant predictors of plasma β-amyloid 
in subjects without T2DM identified in chapter 1, in order to determine whether any 
effects of plasma β-amyloid were independent of these factors. When plasma β-
amyloid 40 was included in the model, additional variables included were eGFR, age 
and height. When plasma β-amyloid 42 was included in the model, the additional 
factor included was eGFR. Each row with corresponding β-amyloid column in the 
table below represents an individual regression model.  
 
 
Table 3-32: Summary of linear regression models with independent variables age, gender, 
systolic blood pressure, HDL cholesterol and total cholesterol with either β-amyloid 40 or 
42 and eGFR, age, height or eGFR respectively. 
Vascular Measurement – Dependent 
Variable 
Aβ40 (pg/ml) Aβ42 (pg/ml) 
Beta p-value Beta p-value 
Reactive Hyperaemia Peak Perfusion (PU) -0.033 0.787 -0.119 0.298 
Reactive Hyperaemia Index (EndoPAT 
units) 
0.057 0.588 -0.075 0.447 
Pulse Wave Velocity (m/s) 0.125 0.161 0.048 0.563 
Common Carotid IMT Right (mm) 0.107 0.262 0.024 0.789 
Mean Bulb IMT Right (mm) 0.165 0.117 -0.036 0.723 
Common Carotid IMT Left (mm) 0.104 0.307 -0.03 0.752 
Mean Bulb IMT Left (mm) 0.3 0.008 0.099 0.359 
Mean SNP Response (PU) 0.007 0.953 -0.039 0.717 
Mean ACh Response (PU) -0.051 0.661 -0.075 0.484 
 
 
According to the linear regression models summarised above, the only significant 
and independent association of β-amyloid 40 in the Dundee non-T2DM cohort is 






 Analysis of Dundee Subjects With T2DM 
 
The above analysis was then repeated in Dundee subjects with T2DM. The first step 
was to determine the association between plasma β-amyloid and biomarkers of 
vascular disease. Either Pearson or Spearman correlations were used, depending on 
the distribution of variables. The Bonferroni method was used to correct for multiple 
comparisons (new p value p=0.003). Scatterplots for significant correlations are 
displayed below.  
 Univariate Correlations in Dundee Subjects with T2DM 
Table 3-33: Summary of univariate correlations of plasma β-amyloid with markers of 
vascular functional or structural change in Dundee subjects with T2DM. 




Reactive Hyperaemia Index (EndoPAT) 
(units) 
Correlation Coefficient -0.063 -0.204 
  Sig.  0.35 0.002 
  N 220 220 
Reactive Hyperaemia Peak Perfusion 
(PU) 
Correlation Coefficient -0.105 -0.35 
  Sig. 0.215 1.90E-05 
  N 142 142 
Pulse wave velocity (m/s) Correlation Coefficient 0.351 0.23 
  Sig. 2.00E-06 0.002 
  N 171 171 
Mean Common Carotid IMT Right (mm) Correlation Coefficient 0.139 0.108 
  Sig. 0.039 0.112 
  N 220 219 
Mean Bulb IMT Right (mm) Correlation Coefficient 0.127 0.004 
  Sig. 0.117 0.963 
  N 153 153 
Mean Common Carotid IMT Left (mm) Correlation Coefficient 0.082 -0.027 
  Sig. 0.218 0.692 
  N 225 225 
Mean Bulb IMT Left (mm) Correlation Coefficient 0.046 -0.008 
  Sig. 0.54 0.919 
  N 180 181 
Mean Peak SNP Response (PU) Correlation Coefficient -0.13 -0.031 
  Sig. 0.076 0.677 
  N 187 186 
Mean Peak ACh Response (PU) Correlation Coefficient -0.078 -0.067 
  Sig. 0.288 0.361 
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Figure 3-30: Scatter plot of β-amyloid 42 with reactive hyperaemia 
(EndoPAT) in Dundee subjects with T2DM, n=220, r=-0.204. 

















































Figure 3-29: Scatter plot of β-amyloid 40 with pulse wave velocity in 
Dundee subjects with T2DM, n=171, r=0.351. 
Figure 3-31: Scatter plot of β-amyloid 42 with peak reactive hyperaemia 




Figure 3-32: Scatter plot of β-amyloid 42 with pulse wave velocity in Dundee 


















The above univariate analyses show that after Bonferroni correction, a significant 
positive correlation is seen between β-amyloid 40 and pulse wave velocity in Dundee 
subjects with T2DM. With regards to β-amyloid 42, significant negative correlations 
can be seen with peak reactive hyperaemia response to temporary blood flow 
occlusion as well as RHI as measured by EndoPAT. As with β-amyloid 40, a significant 




 Linear Regression Models: Dundee subjects with T2DM 
 
As before, the next step was to determine whether any associations of plasma β-
amyloid persists even after adjusting for conventional CVD risk factors as well as 
clinical determinants of plasma β-amyloid identified in the previous chapter.  The 
following linear regression models adjusted for age, gender, total cholesterol, HDL 
cholesterol and peripheral systolic blood pressure and either β-amyloid 40 or 42. 
Where models adjusted for β-amyloid 40, eGFR, insulin and diuretic use was also 
adjusted for. Where models adjusted for β-amyloid 42, eGFR and insulin use was 
also adjusted for. Each row in the table below represents an independent regression 




Table 3-34: Linear regression models with independent variables age, gender, total 
cholesterol, HDL cholesterol and peripheral systolic blood pressure and either β-amyloid 
40 with eGFR, diuretic use and insulin use or β-amyloid 42 and eGFR and insulin use. 
Vascular Measurement – Dependent 
Variable 
Aβ40 (pg/ml) Aβ42 (pg/ml) 
Beta p-value Beta p-value 
Reactive Hyperaemia Peak Perfusion (PU) -0.052 0.619 -0.235 0.021 
Reactive Hyperaemia Index (EndoPAT 
units) 
-0.022 0.772 -0.09 0.228 
Pulse Wave Velocity (m/s) 0.242 0.002 0.178 0.02 
Common Carotid IMT Right (mm) 0.099 0.211 -0.043 0.577 
Mean Bulb IMT Right (mm) 0.082 0.386 -0.028 0.762 
Common Carotid IMT Left (mm) 0.06 0.454 -0.138 0.073 
Mean Bulb IMT Left (mm) 0.016 0.859 -0.014 0.87 
Mean SNP Response (PU) -0.036 0.689 0.076 0.376 
Mean ACh Response (PU) -0.059 0.5 0.074 0.383 
 
The above summary of numerous linear regression models shows that β-amyloid 40 
is significantly and independently associated with increasing pulse wave velocity, and 
that β-amyloid 42 is significantly and independently associated with reduced reactive 
hyperaemia peak perfusion response, even after adjusting for conventional CVD risk 
factors and determinants of β-amyloid. 
 
 Analysis of the Exeter Baseline Cohort: 
 
The analysis performed for the Dundee subgroup was then repeated for the Exeter 
subgroup.  
 
 Univariate Correlations in the Exeter Baseline Cohort 
 
In order to begin exploring how plasma beta amyloid varies with different measures 
of structural and functional change in the Exeter baseline cohort, univariate analysis 
was performed using correlations. Depending on the distribution of parameters, 
either Pearson or Spearman correlations were used. The Bonferroni method 
(dividing standard p=<0.05 by number of comparisons made) was used to adjust for 
multiple comparisons at univariate level. Significant associations after adjustment 





Table 3-35: Summary of univariate correlations of plasma β-amyloid with markers of 
vascular functional and structural change in the Exeter Baseline cohort 
Vascular Measurement Correlation Aβ40 Aβ42 
Reactive Hyperaemia Index 
(EndoPAT) 
Correlation Coefficient 0.075 0.051 
  Sig.  0.228 0.415 
  N 258 258 
Reactive Hyperaemia Peak 
Perfusion (PU) 
Correlation Coefficient 0.077 0.033 
  Sig.  0.228 0.604 
  N 248 248 
Pulse wave velocity (m/s) Correlation Coefficient 0.165 0.074 
  Sig.  0.008 0.241 
  N 253 253 
Mean common carotid artery IMT 
Right 
Correlation Coefficient 0.074 0.04 
  Sig. 0.222 0.516 
  N 272 272 
Mean bulb IMT Right Correlation Coefficient -0.125 -0.075 
  Sig. 0.048 0.239 
  N 249 249 
Mean common carotid artery IMT 
Left 
Correlation Coefficient 0.061 0.015 
  Sig. 0.318 0.812 
  N 269 269 
Mean bulb IMT Left Correlation Coefficient 0.045 0.043 
  Sig. 0.491 0.51 
  N 240 240 
Mean Peak SNP Response  Correlation Coefficient -0.107 0.031 
  Sig. 0.086 0.625 
  N 259 259 
Mean Peak ACh Response Correlation Coefficient -0.066 -0.03 
  Sig. 0.292 0.629 
  N 259 259 
 
The above analysis shows that after Bonferroni correction, no significant correlations 







 Linear regression in the Exeter baseline cohort 
 
As performed previously, a regression model was then built to determine whether 
any associations seen during univariate analysis persisted after adjusting for 
common CVD risk factors. This model adjusted for age, gender, diabetes status, total 
cholesterol, HDL cholesterol as well as factors identified as significant predictors of 
plasma β-amyloid in chapter 1. For β-amyloid 40 in the baseline cohort these were 
eGFR and diuretic use, and for β-amyloid 42 these were eGFR, diuretic use and LDL 
cholesterol. Each row represents a separate linear regression model with the 




Table 3-36: Linear regression models with independent variables of age, gender, diabetes 
status, HDL cholesterol, total cholesterol, systolic blood pressure and either β-amyloid 40 
with eGFR + diuretic use or β-amyloid 42 with eGFR + diuretic use + LDL cholesterol.  
Vascular Measurement Aβ40 (pg/ml) Aβ42 (pg/ml) 
Beta p-value Beta p-value 
Reactive Hyperaemia Peak 
Perfusion (PU) 
0.077 0.259 -0.003 0.968 
Reactive Hyperaemia Index 
(EndoPAT units) 
0.042 0.513 0.005 0.942 
Pulse Wave Velocity (m/s) 0.077 0.259 -0.027 0.606 
Common Carotid IMT Right (mm) -0.026 0.651 0.011 0.857 
Mean Bulb IMT Right (mm) -0.09 0.152 -0.008 0.906 
Common Carotid IMT Left (mm) -0.069 0.258 -0.036 0.563 
Mean Bulb IMT Left (mm) 0.025 0.703 0.118 0.077 
Mean SNP Response (PU) -0.095 0.136 -0.01 0.874 
Mean ACh Response (PU) -0.024 0.711 -0.025 0.702 
 
 
The above linear regression models showed that even after adjusting for 
conventional CVD risk factors and determinants of plasma β-amyloid, no significant 
independent associations were seen with any marker of functional or structural 






  Analysis of Exeter Subjects Without T2DM 
 
The same analysis was then repeated in Exeter subjects without T2DM. Depending 
on the distribution of variables, either the Mann-Whitney or independent T-tests 
were used. The Bonferroni method was used to correct for multiple comparisons, by 
dividing the p value 0.05 by number of comparisons made (adjusted p-value, 
p<0.003). Scatter plots for significant correlations are displayed below.  
 Univariate Correlations in Exeter subjects without T2DM 
 
Table 3-37: Summary of univariate correlation of β-amyloid with markers of vascular 
functional or structural change in Exeter subjects without T2DM. 
Variable Correlation Aβ40 Aβ42 
Reactive Hyperaemia Index (EndoPAT 
units) 
Correlation Coefficient 0.127 -0.084 
  Sig. 0.192 0.385 
  N 108 108 
Reactive Hyperaemia Peak Perfusion 
(PU) 
Correlation Coefficient 0.146 0.181 
  Sig. 0.138 0.065 
  N 105 105 
Pulse wave velocity (m/s) Correlation Coefficient 0.294 0.134 
  Sig.  0.002 0.165 
  N 109 109 
Mean common carotid artery IMT 
Right (mm) 
Correlation Coefficient 0.163 0.146 
  Sig. 0.086 0.126 
  N 111 111 
Mean bulb IMT Right (mm) Correlation Coefficient -0.121 -0.159 
  Sig. 0.224 0.11 
  N 102 102 
Mean common carotid artery IMT Left 
(mm) 
Correlation Coefficient 0.069 0.067 
  Sig. 0.474 0.484 
  N 110 110 
Mean bulb IMT Left (mm) Correlation Coefficient -0.071 -0.101 
  Sig. 0.469 0.304 
  N 105 105 
Mean Peak SNP Response (PU) Correlation Coefficient 0.004 0.129 
  Sig. 0.97 0.191 
  N 105 105 
Mean Peak ACh Response (PU) Correlation Coefficient -0.017 -0.018 
  Sig. 0.865 0.856 
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Univariate correlations were then performed in Exeter subjects without T2DM. After 
Bonferroni correction, the only significant association was a positive correlation 
between β-amyloid 40 and pulse wave velocity.  
 
 Linear Regression Models: Exeter subjects without T2DM 
 
To determine whether any significant independent associations were seen after 
adjusting for common CVD risk factors, the following linear regression models were 
performed. These linear regression models adjusted for established risk factors used 
in the Framingham and ASSIGN CVD risk scores: Age, Gender, SBP, HDL cholesterol 
and Total cholesterol. This model also adjusted for significant predictors of plasma β-
amyloid in subjects without T2DM identified in chapter 1, in order to determine 
whether any effects of plasma β-amyloid were independent of these factors. When 
plasma β-amyloid 40 was included in the model, additional variables included were 
eGFR, age and height. When plasma β-amyloid 42 was included in the model, the 
additional factor included was eGFR. Each row with corresponding β-amyloid column 
in the table below represents an individual regression model.  
Figure 3-33: Scatter plot of β-amyloid 40 with pulse wave velocity in Exeter 





Table 3-38: Linear regression models with independent variables age, gender, systolic 
blood pressure, HDL cholesterol, total cholesterol and either β-amyloid 40 with eGFR + age 
+ height  or β-amyloid 42 with eGFR in Exeter subjects without T2DM.  
Vascular Measurement Aβ40 (pg/ml) Aβ42 (pg/ml) 
Beta p-value Beta p-value 
Reactive Hyperaemia Peak 
Perfusion (PU) 
0.082 0.451 -0.14 0.19 
Reactive Hyperaemia Index 
(EndoPAT units) 
0.085 0.411 0.16 0.148 
Pulse Wave Velocity (m/s) 0.147 0.054 0.132 0.089 
Common Carotid IMT Right (mm) 0.036 0.692 0.153 0.099 
Mean Bulb IMT Right (mm) -0.158 0.122 -0.189 0.078 
Common Carotid IMT Left (mm) -0.094 0.331 -0.01 0.918 
Mean Bulb IMT Left (mm) -0.043 0.66 -0.064 0.533 
Mean SNP Response (PU) 0.04 0.71 0.176 0.107 
     
Mean ACh Response (PU) 0.095 0.379 0.104 0.341 
 
After adjusting for conventional CVD risk factors as well as determinants of β-
amyloid levels, no significant independent associations were seen in Exeter subjects 
without T2DM.  
 
 
 Analysis of Exeter Subjects With T2DM 
 
Next, the Exeter subjects with T2DM were examined. The first step was to determine 
the association between plasma β-amyloid and biomarkers of vascular structural or 
functional change. Either Pearson or Spearman correlations were used, depending 
on the distribution of variables. The Bonferroni method was used to correct for 
multiple comparisons (new p value p<0.003). Scatterplots for significant correlations 









 Univariate Correlations in Exeter subjects with T2DM 
 
3-39: Summary of univariate correlations of plasma β-amyloid with markers of vascular 
functional or structural change in Exeter subjects with T2DM. 
Variable Correlation Aβ40 Aβ42 
Reactive Hyperaemia Index (EndoPAT 
units) 
Correlation Coefficient 0.054 0.129 
  Sig. 0.515 0.115 
  N 150 150 
Reactive Hyperaemia Peak Perfusion 
(PU) 
Correlation Coefficient 0.031 -0.08 
  Sig. 0.713 0.34 
  N 143 143 
Pulse wave velocity (m/s) Correlation Coefficient 0.109 0.056 
  Sig. 0.192 0.502 
  N 144 144 
Mean CC IMT Right (mm) Correlation Coefficient 0.022 -0.021 
  Sig. 0.786 0.792 
  N 161 161 
Mean CC Bulb IMT Right (mm) Correlation Coefficient -0.124 -0.022 
  Sig. 0.133 0.793 
  N 147 147 
Mean CC IMT Left (mm) Correlation Coefficient 0.062 -0.012 
  Sig. 0.435 0.878 
  N 159 159 
Mean CC Bulb IMT Left (mm) Correlation Coefficient 0.121 0.13 
  Sig. 0.163 0.134 
  N 135 135 
Mean Peak SNP Response (PU) Correlation Coefficient -0.229 -0.055 
  Sig. 0.004 0.495 
  N 154 154 
Mean Peak ACh Response (PU) Correlation Coefficient -0.155 -0.086 
  Sig. 0.055 0.289 
  N 154 154 
 
 
Again, after Bonferroni correction, no significant correlations were seen for neither 









 Linear Regression Models: Exeter Subjects with T2DM. 
 
As before, the next step was to determine whether any associations of plasma β-
amyloid persists even after adjusting for conventional CVD risk factors as well as 
clinical determinants of plasma β-amyloid identified in the previous chapter.  The 
following linear regression models adjusted for age, gender, total cholesterol, HDL 
cholesterol and peripheral systolic blood pressure and either β-amyloid 40 or 42. 
Where models adjusted for β-amyloid 40, eGFR, insulin and diuretic use was also 
adjusted for. Where models adjusted for β-amyloid 42, eGFR and insulin use was 
also adjusted for. Each row with corresponding β-amyloid column in the table below 
represents an independent regression model. 
 
Table 3-40: Linear regression models with independent variables age, gender, systolic 
blood pressure, HDL cholesterol, total cholesterol and either β-amyloid 40 with  eGFR + 
insulin + diuretic use or β-amyloid 42 with eGFR + insulin use in Exeter subjects with 
T2DM. 
Vascular Measurement Aβ40 (pg/ml) Aβ42 (pg/ml) 
Beta p-value Beta p-value 
Reactive Hyperaemia Peak 
Perfusion (PU) 
0.057 0.539 -0.098 0.29 
Reactive Hyperaemia Index 
(EndoPAT units) 
0.02 0.819 0.05 0.569 
Pulse Wave Velocity (m/s) -0.017 0.807 -0.075 0.285 
Common Carotid IMT Right (mm) -0.079 0.327 -0.065 0.411 
Mean Bulb IMT Right (mm) -0.036 0.669 0.079 0.34 
Common Carotid IMT Left (mm) -0.073 0.376 -0.057 0.477 
Mean Bulb IMT Left (mm) 0.077 0.388 0.178 0.045 
Mean SNP Response (PU) -0.178 0.04 -0.073 0.396 
Mean ACh Response (PU) -0.109 0.206 -0.078 0.36 
 
Interestingly, after adjusting for conventional CVD risk factors as well as clinical 
determinants of β-amyloid 40 and 42, significant independent associations were 
seen with β-amyloid 40 and mean peak SNP response as well as β-amyloid 42 with 









 Summary of Key Findings 
 
 SUMMIT Baseline cohort 
o β-amyloid 40 is significantly and independently associated with 
increased peak reactive hyperaemia response and pulse wave velocity 
o β-amyloid 40 is also significantly and independently associated with 
reduced response to SNP and ACh iontophoresis 
o β-amyloid 42 was significantly and independently associated with a 
reduced reactive hyperaemia response 
o At enrolment into the study, higher β-amyloid 40 levels were 
associated with increased number of LEAD cases 
o No associations were seen with follow up adverse cardiovascular 
outcomes or overall mortality 
 
 SUMMIT Non-T2DM cohort  
o β-amyloid 40 is significantly and independently associated with 
increased pulse wave velocity 
o β-amyloid 42 levels were significantly associated with increased peak 
response to SNP iontophoresis 
 
 SUMMIT T2DM cohort 
o β-amyloid 40 is significantly and independently associated with 
increased peak reactive hyperaemia response and pulse wave velocity 
o β-amyloid 40 is also significantly and independently associated with 
reduced response to SNP and ACh iontophoresis 
o No significant independent associations were seen with β-amyloid 42 
o At enrolment into the study higher β-amyloid 40 levels were 
associated with a higher number of LEAD cases 
 
 Dundee Baseline Cohort 
o The Dundee and Exeter cohorts were significantly different across a 
number of different baseline clinical parameters 
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o β-amyloid 40 is significantly and independently associated with 
increased pulse wave velocity 
o β-amyloid 42 was significantly and independently associated with a 
reduced reactive hyperaemia response 
 
 Dundee Non-T2DM Cohort 
o β-amyloid 40 is significantly associated with increased left-sided bulb 
IMT 
 
 Dundee T2DM Cohort 
o β-amyloid 42 is significantly and independently associated with 
increased pulse wave velocity 
 
 Exeter Baseline Cohort 
o No significant independent associations were seen 
 
 Exeter Non-T2DM Cohort 
o No significant independent associations were seen 
 
 Exeter T2DM Cohort 
o β-amyloid 40 is also significantly and independently associated with 





















β-amyloid has previously been extensively investigated primarily in the context of 
AD. However, in recent years a number of studies have shown that it may play a role 
in CVD. The present study looked at the association of plasma β-amyloid 40 and 42 
with markers of functional and structural vascular change as well as with 
cardiovascular outcomes over a follow up period of 4-6 years. To date, this is the first 
comprehensive study associating both β-amyloid 40 and 42 with a multitude of 
vascular structural and functional assessments. Additionally, it is the first study to 
date to look at these relationships in subjects with and without diabetes separately.  
 
 Findings from the SUMMIT Cohort – β-amyloid and Arterial Stiffness 
 
Several studies have previously reported a strong association between β-amyloid 40 
and arterial stiffness (38,120,121). These findings were reproduced in the present 
study, where this association persisted even after adjusting for established CVD risk 
factors as well as clinical determinants of plasma β-amyloid levels identified in 
chapter 2. This held true in the SUMMIT baseline cohort, as well as subjects with and 
without T2DM when looked at individually. Therefore, these findings reinforce those 
previously published in the literature. In addition, by controlling for determinants of 
plasma β-amyloid levels, this study suggests that a direct relationship could exist 
between β-amyloid and pulse wave velocity, and that these findings are not merely 
as a result of an association between other factors such as renal function. However, 
the exact mechanism of how β-amyloid could contribute to arterial stiffness is still 
unknown. 
In general, increasing arterial stiffness is considered to be a paradigm of vascular 
ageing and is thought to occur primarily as a result of changes to the extracellular 
matrix (ECM). These changes include increased collagen deposition, and reduced 
elastin concentrations (122). However, whether β-amyloid contributes to the 
process via the same set of mechanisms is unclear. A possible explanation for how β-
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amyloid could alter arterial stiffness relates to the extensive research done in the 
context of CAA. CAA is a poorly understood disease entity characterised by β-
amyloid deposition in small to medium sized blood vessels of the brain. It manifests 
clinically as recurrent, often debilitating intracerebral haemorrhages and associated 
haemorrhagic stroke syndromes. Pathologically, it results in stenosis of the vessel 
lumen, fibrinoid necrosis and microaneurysm formation (123). In the context of this 
pathological state, β-amyloid has been shown to be toxic to VSMCs, and to result in 
changes to the ECM component of the cerebral vasculature. In fact, the steps by 
which β-amyloid results in changes to vascular structure have been well 
documented. In the first stages, β-amyloid is found to accumulate at the basal 
lamina (124,125). As CAA progresses, β-amyloid deposition extends beyond the basal 
lamina into VSMC layers. Once it has reached this layer, VSMC death occurs in a dose 
dependent manner and can result in a complete lack of a functional response to 
vasoactive stimuli (126). With yet more advanced stages of CAA, the vascular media 
is completely replaced by β-amyloid deposits and lacks any surviving VSMCs. Even at 
these later stages, the endothelial cells remain functional, but are seen to have 
abnormal morphologies (127).  
In terms of β-amyloid’s effects on the ECM, in vitro studies have shown that β-
amyloid can induce MMP-9 activity (127). Interestingly, MMP-9 has been associated 
with systemic arterial stiffness in a range of different studies. Yasmin et al. report 
that increased levels of MMP-9 and increased elastase activity is associated with 
increasing arterial stiffness in both healthy individuals and subjects with isolated 
systolic hypertension (128). The same group has also shown that single nucleotide 
polymorphisms (SNPs) in the MMP-9 gene significantly affect arterial stiffness in 
healthy individuals (129). Therefore, the ability of β-amyloid to induce MMP-9 levels 
could be a potential explanation for the strong association between increased 
plasma β-amyloid 40 levels and increasing arterial stiffness. Unfortunately, MMP-9 
was not among the numerous MMPs measured in the SUMMIT database. In the 
future, measuring MMP-9 in these samples could be of interest in an attempt to 




 β-amyloid and the Vascular Response to Acetylcholine and Sodium 
Nitroprusside 
 
In light of the effects of β-amyloid on VSMCs described above, the associations 
between plasma β-amyloid and laser Doppler imaging with iontophoresis data must 
be discussed in the context of microvascular function. The present study is the first 
to investigate the association between plasma β-amyloid and vascular 
responsiveness to ACh and SNP assessed by means of laser Doppler imaging and 
iontophoresis. When looking at univariate correlations, a significant negative 
correlation between plasma β-amyloid 40 levels and peak perfusion response to SNP 
and ACh exists. More importantly, these significant associations persist in the 
SUMMIT baseline and SUMMIT T2DM cohorts even after adjusting for conventional 
CVD risk factors and significant clinical determinants of plasma β-amyloid 40 levels. 
Several important points need to be discussed as a result of these observations.  
Firstly, a significant association between plasma β-amyloid 40 and peak SNP or ACh 
was not seen in SUMMIT subjects without T2DM. It is possible, that this relationship 
is specific to subjects with T2DM, and that the analysis of the SUMMIT baseline 
cohort was skewed by the comparatively larger number of subjects with T2DM. 
However, this is unlikely, as the regression model in the SUMMIT baseline cohort 
adjusted for diabetes status. Therefore, the more likely explanation for this 
observation is that the cohort of SUMMIT subjects without T2DM was the smallest 
and possibly underpowered to demonstrate any associations. Indeed, even strong 
associations seen in the baseline cohort and T2DM cohort disappeared in the 
analysis looking at Exeter and Dundee subgroups separately, which was 
understandably associated with a large reduction in the number of subjects.  
Another important point that needs to be discussed is the significant association 
with both peak ACh and peak SNP responses. This could be interpreted in different 
ways. Firstly, it is possible that increased β-amyloid 40 is associated with reductions 
both endothelium dependent and endothelium independent vasodilator responses. 
However, it is also possible that increased β-amyloid 40 is only associated with 
endothelium independent pathways (SNP response), but because the response to 
ACh targets steps proximal in the pathway, the response to ACh is also diminished. 
Literature findings related to this matter provide little explanation as they are largely 
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conflicting. As discussed in the previous section, β-amyloid has been shown to cause 
VSMC death (37), which would understandably result in a diminished response to 
SNP administrations. However, numerous in vitro studies have shown that β-amyloid 
exerts vasoactive properties in an endothelium dependent manner. Indeed, findings 
from studies in mice by our group would also suggest that β-amyloid exerts its 
effects in an endothelium dependent manner. This leads on to another interesting 
point for discussion, as in the preceeding mouse study by our research group, β-
amyloid 42 as opposed to 40 was found to be the main culprit. In the present study, 
while β-amyloid 42 was significantly associated with increased peak response to SNP 
in one regression model (SUMMIT subjects without T2DM), this was by no means a 
consistent observation and is possibly due to chance. Nevertheless, findings from 
our preceeding animal study are in direct contrast with current findings. It is possible 
that these discrepancies are due to inter-species variation.  
 
 β-amyloid and Reactive Hyperaemia  
 
Further adding to the dilemma surrounding the association of plasma β-amyloid with 
markers of functional change in the vasculature are the present findings of a positive 
association between reactive hyperaemia and β-amyloid 40 and while a significant 
negative association between β-amyloid 42 and reactive hyperaemia in the SUMMIT 
baseline cohort.  A significant positive association was also seen between β-amyloid 
40 and reactive hyperaemia in the SUMMIT T2DM cohort. This would suggest that 
higher plasma β-amyloid 40 levels are associated with better reactive hyperaemia 
responses to temporary blood flow occlusion. This seems to contrast other results in 
this study, as similarly to the vascular response to ACh, reactive hyperaemia is a 
response mediated primarily in an endothelium-dependent manner. However, it is 
well recognised that the reactive hyperaemia response occurs via mechanisms 
different to those involved in the vasodilator response to ACh. It is thought, that 
during temporary blood flow occlusion, vasodilator metabolites such as adenosine 
accumulate due to the state of tissue hypoxia. These cause downstream 
vasodilation. As the blood flow is restored, down stream vasodilation causes reduced 
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resistance to blood flow, which in turn increases the shear stress on upstream 
vessels (130). However, how β-amyloid impacts on this process and why differing 
effects are seen when assessing different forms of endothelium dependent response 




 β-amyloid and cIMT 
 
To date, no studies have looked directly at the association between β-amyloid and 
cIMT thickness. In the main analysis of the present study, significant associations 
between plasma β-amyloid 40 levels and right sided cIMT existed, but only when 
performing univariate analyses. After adjusting for conventional risk factors and 
clinical determinants of β-amyloid, β-amyloid 40 was only significantly associated 
with increasing cIMT in the Dundee Non-T2DM cohort. Therefore, it is possible that 
any associations within the univariate analysis were due to chance.  
 
 
 β-amyloid and Cardiovascular Outcomes 
 
One previous study has reported that after adjusting for age, gender, eGFR, CRP, 
Troponin T and left ventricular ejection fraction, plasma β-amyloid 40 independently 
predicted cardiovascular death as well as major adverse cardiac events in patients 
with a history of coronary heart disease (38). In the present study, neither plasma β-
amyloid 40 nor 42 were found to be significant predictors of any cardiovascular 
events or overall mortality. While it is possible that β-amyloid is not of prognostic 
value when it comes to CVD risk prediction, a likely explanation is that this study was 
underpowered to demonstrate any associations. Indeed, the study by 
Stametelopoulos et al. recruited almost double the number of subjects included in 
this database (38).  
 
 Effect of diabetes status on associations of β-amyloid with markers of 




In the present study, a number of subgroup analyses were performed with subjects 
divided based on diabetes status. An interesting and consistent observation 
throughout the analyses of the SUMMIT and Exeter cohorts was that β-amyloid was 
significantly and independently associated with a larger number of structural and 
functional markers of vascular health in the T2DM subgroups when compared to the 
non-T2DM subgroups. However, in analyses of the SUMMIT and Dundee cohorts, the 
grouped baseline analysis (both T2DM and Non-T2DM subjects) revealed the largest 
number of significant independent associations. Therefore, a likely explanation for 
the stronger and more numerous associations seen in T2DM subgroups compared to 
non-T2DM subgroups, is the number of subjects included in individual analyses and 
therefore statistical power. Therefore, it is unlikely that β-amyloid associates 
uniquely with vascular markers in T2DM. This is an important observation, as the 
animal study this project was based on suggested that β-amyloid may be a 
contributor to vascular dysfunction in a manner unique to T2DM and diet-induced 
obesity models.  
 Limitations of Study:  
 
There are several potential limitations of this study that must be considered. Firstly, 
although analysis of the grouped cohort revealed some interesting associations of 
plasma β-amyloid with markers of vascular structural and functional health, the 
subgroup analysis by centre only partially reproduced these observations. The most 
likely explanation for this is that the sub-group analysis by centre was associated 
with too large a reduction in number of subjects. 
Another observation that must be addressed, is the small group of subjects in the 
Exeter cohort with extremely low levels of both β-amyloid 40 and 42 (see scatter 
plots from the Exeter sub-group analysis). Although these are seemingly outliers, 
they were included in any analysis due to the inability to determine the reason 
behind such observations. The levels of β-amyloid measured in this group was still 
well within the minimum detection limit for the assay used. Additionally, these 
samples were scattered across a number of assay plates, suggesting that is unlikely 
to be due to an individual assay failure. As β-amyloid levels were only measured as a 
one-off measurement due to the limited amount of plasma available and the need to 
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also measure other circulating biomarkers, it was impossible to exclude a qualitative 
problem with the sample. When looking at the characteristics of this small subgroup, 
there was no single factor that would link these subjects together. Across the group 
a range of different ages, BMIs, blood pressures and medications can be observed. In 
the future, it would be interesting to determine the genotype of these individuals. 
Given that this seemingly outlying group of subjects could not be excluded from the 
cohort and was present only in the subjects from Exeter, it is possible that it skewed 
some of our results and contributed to some of the conflicting results observed 
between the two cohorts. To resolve this, an analysis excluding subjects with 
extremely low levels of β-amyloid could be carried out and used as a reference point 
to determine if outliers account for some of the differences between centres.  
 
Although we lack knowledge regarding the source of β-amyloid, the findings in this 
study perhaps help shed light on the potential elimination mechanisms. In fact, one 
of the strongest associations uncovered in Chapter 2 was the strong association of 
eGFR and other related markers of renal function with plasma β-amyloid in both 
diabetic and non-diabetic populations. Should β-amyloid play a direct role in the 
development of vascular disease it is possible that renal elimination could be of 
therapeutic significance not only for this disease entity, but also for other β-amyloid 
associated pathological states including AD or cerebral amyloid angiopathy. This 
would, however, only hold true under the assumption that plasma β-amyloid levels 
are at an equilibrium with cerebral β-amyloid levels, and that a transport mechanism 
exists between the two.  
The strong association between β-amyloid and eGFR however, brings with it a large 
set of limitations for plasma β-amyloid as a potential biomarker. Although 
pathological processes affecting the kidneys and resulting in lower eGFR are 
plentiful, the commonest cause of end stage renal failure in the developed world is 
diabetic nephropathy (131). Therefore, it is debatable whether β-amyloid would be a 
useful biomarker of CVD in patients with diabetes. Although it is possible that β-
amyloid could be a useful predictor of cardiovascular disease in earlier stages of 
diabetes, another complicating matter is the observation that patients in the early 
stages of type 2 diabetes experience renal hyperfiltration as a result of osmotic 
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diuresis (132). Indeed, it is now well accepted in a number of different 
pathophysiological models of diabetic nephropathy that hyperfiltration is the first 
stage of the pathological process (132). However, if β-amyloid is shown to be a direct 
contributor to the pathological process of CVD as opposed to being only a coincident 
biomarker, any effects of eGFR on plasma β-amyloid levels could become less 
important.  
This directly relates to another possible limitation of β-amyloid as a biomarker given 
its strong association with renal function. Renal dysfunction itself is a very strong risk 
factor for cardiovascular disease, in fact, in patients with chronic kidney disease, 
cardiovascular disease is one the commonest cause of death (133). Therefore, it is 
possible that β-amyloid could simply be acting as a biomarker of renal function, with 
poor renal function being the underlying causal association. 
 
When looking at results from the outcome analysis, several limitations can be 
discussed. Firstly, although plasma β-amyloid was not shown to be a significant 
predictor of cardiovascular outcomes at end of follow up, on most occasions neither 
were classical risk factors such as total cholesterol, HDL cholesterol, diabetes status, 
age or systolic blood pressure also. This could be due to a number of different 
reasons, the most likely being that there were very small amounts of outcomes 
accumulated over the course of the follow up period. In total, there were 18 deaths, 
17 diagnoses of claudication, 12 transient ischaemic attacks, 6 strokes, 20 diagnoses 
of unstable angina and 14 cases of acute myocardial infarction. When considered as 
individual entities, the numbers in each category are relatively low and as such can 
result in a significantly underpowered analysis. However, when grouping all 
outcomes into a composite dependent variable, conventional risk factors for 
cardiovascular disease still remained statistically insignificant. Additionally, although 
a subgroup analysis dividing subjects based on diabetes status was performed for all 
other analyses, little value was thought to be gained from doing so in outcome 
analysis, as these would underpower statistical tests even further. Ideally, follow up 
would continue for a longer period of time to allow for the accumulation of more 






β-amyloid is a peptide molecule best known for its role in the development of AD. 
Surprisingly, despite an evidence base and research funding far bigger than most 
other diseases, a large number of unknowns continue to surround β-amyloid. 
Perhaps unusually, this study investigated β-amyloid in the context of a different 
disease process, CVD. The background to this study stems from currently 
unpublished findings from previous animal studies carried out by our research 
group. Briefly, plasma β-amyloid was shown to be increased in mice with diet 
induced obesity, and increased plasma β-amyloid 42 levels by means of β-amyloid 42 
infusions were associated with reduced vascular responsiveness to ACh and SNP. 
Lowering β-amyloid, by pharmacologically inhibiting the enzyme responsible for 
mediating its rate limiting step, was shown to restore vascular responsiveness. 
 
In light of these findings, this thesis therefore aimed to translate these findings into 
the human population. More specifically, this thesis aimed to investigate the 
association of β-amyloid with markers of vascular structural and functional change 
as well as with clinically manifest CVD. Additionally, in an attempt to shed some light 
on the processes that dictate β-amyloid kinetics in the circulation, this project also 
investigated the clinical determinants of plasma β-amyloid. These objectives were 
fulfilled by statistically analysing the pre-existing SUMMIT database in combination 
with retrospective measurement of plasma β-amyloid by the Immunoassay 
Biomarker Core Laboratory situated in Ninewells Hospital, Dundee.  
 
The first analysis in this study (chapter 2) looked at the clinical determinants of 
plasma β-amyloid in our SUMMIT cohort. Although limited information on 
associations of β-amyloid with determinants such as eGFR previously existed, there 
is no information regarding how well these findings translate to other populations 
such as younger subjects or subjects without dementia. Although a relatively limited 
analysis, this process helped highlight the strength of the relationship between eGFR 
and plasma β-amyloid, but also unveiled some new interesting associations including 
a relationship between insulin use and diuretic use with plasma β-amyloid levels. 
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Not only did this analysis enable us to then adjust for these variables in models 
looking at β-amyloid in the context of CVD, but will also hopefully be of value in the 
field of AD, where plasma β-amyloid has been a much sought after biomarker, but 
also one that to date remains conflicting and elusive.  
 
The second analysis aimed to translate findings from previous animal studies into 
the human population. An analysis of the SUMMIT cohort confirmed previous 
reports of an independent association of β-amyloid 40 with arterial stiffness as 
measured by pulse wave velocity. Additionally, β-amyloid 40 was also shown to be 
independently associated with impaired peak response to SNP and ACh in the 
SUMMIT baseline and T2DM cohorts, as assessed by means of laser Doppler 
iontophoresis. Less consistent findings in this analysis suggest that a possible 
independent association may exist between β-amyloid 40, cIMT and reactive 
hyperaemia as well as β-amyloid 42 and reactive hyperaemia. These associations 
may be of interest in future research. Lastly, in the present study, β-amyloid 40 or 42 
were not found to be independently associated with CVD outcomes in our cohort 
over a follow-up period of 4-6 years. However, this analysis was likely underpowered 
and therefore reliable conclusions cannot be drawn solely on the basis of our data. 
Again, this area may be worth revisiting in the future, with more robust databases 
and longer follow up periods.  
 
Overall, this translational study supports some of the findings previously reported by 
our group as well as other research groups. Although a number of unanswered 
questions remain, and the potential predictive value of β-amyloid has not been 
unveiled, it is clear that β-amyloid has affinity for the vasculature and is associated 
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